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In the late 1990s Portugal was faced with serious 
challenges in relation to problematic drug use and 
drug dependency. Action was required and a number 
of innovative measures were adopted to meet these 
challenges. In particular, there was a focus on those people 
who, for many reasons, including social marginalization, 
were not turning to conventional treatment services, or 
for whom those services were not effective.
In the first instance, it was necessary to address 
a main reason people may not want to come forward. 
Thus, a new law was adopted which decriminalized 
drug consumption and centres instead on the need for 
therapeutic evaluation, rehabilitation and reducing drug 
related harms.
This step led to the approval of a legal framework 
that emphasised comprehensive harm reduction 
interventions and which took effect with the Decree Law 
183/2001 of 21st June.
Law reform alone, however, is not enough. 
The multi-faceted dimension of the issue and the 
interaction between diverse areas of public services 
(Protection Services, Education, Employment, Housing, 
amongst others) demand holistic approaches – and 
partnership. When it comes to harm reduction, civil 
society organizations, with their specific local knowledge 
and relationships with those most at risk, are often the 
most appropriate entities to implement these types of 
interventions.
This has long been recognized in Portugal and, 
over the past decade, the Institute for Drugs and Drug 
Addiction (Instituto da Droga e da Toxicodependência, 
IDT), has defined as one of its priorities the creation of 
the National Network of Harm Reduction by establishing 
partnerships with civil society organizations. According 
to an independent evaluation of Portugal’s National 
Strategy in the Fight against Drugs (1999-2004), harm 
reduction, based on this partnership with civil society 
organizations, was considered one of the key strengths 
of the framework.
Today, the strategic response to drug-related harms 
in Portugal remains largely based on the creation of 
partnerships between the public and social sectors.
This public-social partnership (which also includes 
the private sector) has enabled positive results not just in 
relation to drug use or health harms, but across a wide 
range of important areas; and not just to individuals, but 
to communities:
  A reduction in drug-related crimes, and a greater 
sense of security in the community
  A reduction in discarded drug paraphernalia in the 
community
  A reduction in risk behavior and the subsequent 
reduction in the transmission of infectious diseases 
– central to our public health priorities
  Improved data quality and research on the 
prevalence and incidence of various infectious 
diseases among people who use drugs, which in 
turn informed programmes.
The constant dynamic interaction between the IDT 
and civil society organizations clearly translates into added 
value with gains for both sides. These gains are in turn 
fostering an increased knowledge and understanding of 
drug use and related harms in Portugal. It is a partnership 
that has informed the best means of intervention, and 
enabled partner organizations to achieve better results.
From an economic point of view, and considering 
the current financial crisis, the existence of this network 
of partners enables the implementation of a greater 
number of evidence-based solutions in the field, with a 
decreased cost burden to each entity given that costs are 
being spread amongst them.
I cannot, as President of the IDT and National 
Coordinator for issues involving Drugs, Drug Addiction 
and Alcohol Abuse, commend highly enough the 
fundamental role of civil society in reducing drug related 
harms for the benefits of individuals and society.
This report represents a window into where we are 
in addressing drug use and related harms, and which 
factors continue to challenges effective responses. It 
also provides a valuable insight into how civil society 
organisations are contributing to the reduction of drug 
related harms across Europe.  To all policy makers and 
politicians who are as interested as I am in meeting the 
challenges we continue to face in relation to drugs, I urge 
you to read it, learn from it, and support this vital work.
João Castel-Branco Goulão
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introduction
1.1 WHAt Is  tHe eURoPeAn 
HARM ReDUCtIon netWoRk 
(eURoHRn)?
the european Harm Reduction network, or 
euroHRn, was formed in 2009 by ten civil society 
organisations with a shared interest in advocating 
for and sharing knowledge on harm reduction within 
europe.
euroHRn works to reduce the health and social 
harms related to drugs and the policy environment, 
by promoting the human rights and health of people 
who use drugs through collective advocacy, research 
and information exchange. 
the overall objective of euroHRn is to expand 
the knowledge base of harm reduction in europe, 
raise awareness of drug-related harms, and promote 
and support public health and human rights based 
responses to drug use across europe.
euroHRn is comprised of three sub-regional 
networks (sRns) covering north, south and eastern 
europe and managed by a coordinator based at Harm 
Reduction International (formerly known as the 
International Harm Reduction Association). the sRns 
aim to establish a pool of local experts and contacts, 
engage in local advocacy opportunities, disseminate 
harm reduction news and information, and mobilise 
resources to support activities and ensure the 
sustainability of the network. 
eURoHRn AIMs to:
  Facilitate networking at European, sub-regional 
and national level
  Advocate for harm reduction in the European 
region
  Map the state of harm reduction and drug user 
organising in Europe
  Establish and promote models of meaningful 
participation of people who use drugs and their 
associations
1.2 AIMs AnD oBjeCtIVes oF tHIs 
RePoRt 
This report presents the findings of the EuroHRN 
civil society audit, an activity aimed at collating 
existing epidemiological and service coverage data 
and consulting with experts in order to map key issues 
for harm reduction in Europe. This includes coverage of 
harm reduction interventions, policies and civil society 
advocacy priorities. 
A complementary questionnaire was disseminated 
to focal points in each EuroHRN member country to 
understand the barriers to accessing these services at the 
national and local levels.
This activity aims to provide a snapshot of the 
current state of harm reduction across the region, provide 
a baseline for EuroHRN and civil society in the region and 
act as a regional advocacy and planning tool.
1.3 MetHoDoLoGy
The information collated in Sections 2 and 3 
of this report was gathered using the latest existing 
data sources, including research and reports from 
the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA), multilateral agencies, international 
non-governmental organisations and expert opinion 
from civil society and drug user organisations working in 
the harm reduction field in Europe.  
Countries and regions were identified based on 
the coverage and membership of the European Harm 
Reduction Network. 1 
1. See www.eurohrn.eu for more details. 
8Therefore, this report examines the sub-regions of 
Eastern Europe, North Europe and South Europe. Civil 
society focal points within each country were identified 
through consultations with the EuroHRN steering group 
and other key partners.
Unless otherwise indicated, statistical data was 
sourced from and peer reviewed by the EMCDAA. The 
chapters in Section 3 were peer reviewed by coordinators 
of the sub-regional networks and other experts in the 
field (see Acknowledgements). 
In addition to secondary data, a qualitative 
questionnaire2 examining harm reduction policies, 
interventions, barriers to service access and scale up 
and national advocacy priorities was disseminated to 
civil society focal points in each of 36 countries between 
November 2010 and January 2011. Responses from 28 
countries were returned (see sub-regional chapters for 
more details) within the timeframe provided.
1.4 LIMItAtIons 
This report aims to provide a snapshot of harm 
reduction programmes, barriers to access and advocacy 
priorities for EuroHRN member countries, and as such 
has several limitations. It does not provide a systematic 
overview or evaluation of service coverage and quality 
implemented in the region. Qualitative responses and 
anecdotal data gathered through the questionnaires 
disseminated to national civil society focal points aim to 
provide some indication of potential barriers to service 
access, scale up and quality, as well as suggest directions 
for further research and advocacy by EuroHRN, its 
partners and member countries. 
This report draws heavily on data collected by the 
EMCDDA on the epidemiology of drug use and coverage 
of key harm reduction interventions in Europe. The data 
presented here represents the most reliable estimates 
currently available; however, lack of uniformity in 
measures, data collection methodologies and definitions 
renders cross-national comparisons challenging.  Any 
limitations on reliability are indicated within the text. 
The significant data gaps point to the need for improved 
monitoring and evaluation systems and data reporting 
on these issues in some parts of Europe. 
Where information is gathered through the civil 
society focal points, this is indicated within the text. 
2. The questionnaire is available online at www.eurohrn.eu or by 
writing to eurohrn.audit@ihra.net. 
1.5 stRUCtURe oF tHe RePoRt
Section 1 provides a brief introduction to the 
EuroHRN and to the information presented in this report.
Section 2 comprises four parts. The first two, 
Drug use and Drug-related harms, provide a general 
overview of the most recent data on drug use trends 
and selected drug-related harms in the region. The third 
part summarises findings on harm reduction coverage, 
barriers to service access and scale up across the region, 
as well as emerging advocacy issues for Europe. Finally, 
advocacy priorities for civil society emerging out of this 
exercise are presented for Europe and for the three sub-
regions.
Section 3 presents region- and country-specific 
findings for each of the sub-regions covered by the 
EuroHRN: Eastern Europe, North Europe and South 
Europe. Within each sub-regional chapter, text boxes 
highlight relevant emerging issues and innovative harm 
reduction practices in the region.
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2. Drug use, 
Drug-relateD 
harms anD harm 
reDuction in europe
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harm reDuction 
in europe: past, 
present anD 
future
Harm reduction programmes emerged in 
Europe during the 1980s in response to HIV and 
Hepatitis C epidemics among people who inject drugs. 
Programmes such as needle and syringe exchange 
(NSPs) and opioid substitution treatment (OST) spread 
rapidly across Europe and beyond. Within a decade, 
such programmes  had gained broad acceptance and 
were being implemented across much of Europe and 
elsewhere. Soon after, harm reduction approaches 
became an integral component of the European 
Union’s drug strategy. 
Three decades later, in 2011, Europe is still 
the birthplace of many innovative harm reduction 
practices, and European countries feature among 
those with the highest coverage of harm reduction 
programmes in the world. Several European countries 
have seen dramatic reductions in HIV prevalence 
among people who inject drugs, which has been 
attributed to the early implementation and scale up 
of harm reduction programmes. These successful 
outcomes have formed the basis of UN targets for 
harm reduction programme coverage. 
However, harm reduction in Europe is by no 
means universal: in some countries the programmes 
are too small to have a measureable impact on drug-
related epidemics; in other parts of the region long-
standing harm reduction programmes are under 
threat. A concerted effort from the harm reduction 
community and policy makers will be needed to 
protect and improve harm reduction responses across 
Europe in the face of economic hardship, austerity and 
cuts. 
12
Table 2.1: Drug injecting and related harms in Europei
Country or 
territory
People who 
inject drugs1 
Prevalence 
of injecting 
drug use in 
the adult 
population 
(rate per 
1000 in 
ages 15-
64)2 
HIV prevalence 
among people 
who inject drugs 
(%) 3
Hep C prevalence 
among people who 
inject drugs  (%)4
Hep B (HBsAg) 
prevalence 
among people 
who inject 
drugs (%) 5
Prevalence of 
drug injecting 
among  prisoners 
(%) 6
HIV 
prevalence 
among 
prisoners 
who inject 
drugs (%)7
Hep C 
prevalence 
among 
prisoners 
who inject 
drugs (%)7
Hep B 
(HBsAg) 
prevalence 
among 
prisoners 
who inject 
drugs (%)7
Drug 
related 
deaths8
North Europe
Austria
12,000 – 
23,000*
2.19 – 
4.19*
1.0-10.7 47.1 –  52.6 169
Belgium 
23,200 – 
28,400*
3.46 – 
4.24*
3.3 – 6.4 (S) 27.0 – 82.7 (S) 1.9 – 4.0 (S) 4.0
0.3 
(Flemish) 
1.1 
(French)*
17.4(S) * 
(Flemish) 
27.7(S) 
(French)
2.2* – 5.4
Denmark
10066-
16821
2.8-4.7 2.1 52.5 0.0* 85.0*(S) 211
Finland
12200 - 
19700
4.5 0.1 – 1.3 21.4 – 56.4 0.1 21.4 169
Germany
78,000 – 
110,500b
1.4 – 2.0b 3.4 75 (S) 22.0 1.4 - 18*(S) 82.5*(S) 1449
Ireland 
4,694 – 
7,884*
2.0 – 
3.37*
12.5 (S) 72.3 (S) 0.0 (S) 3.5 - 5.8c * 71.7*-81.3* 185
Luxembourg 1253-1919 3.9-6.0 1.8 71.8 – 90.7 3.9 31.0 4.3* 90.7 10
Netherlands 2211 - 4321 0.29 1.7 –  8.2 (S) 64.6 – 86.2 (S) 129
Norway
8,599-
12,038
2.7-3.8 2.8 74.1 1.2 (S) 275
Sweden 29,513d 4.9d 0.0 – 8.4(S) 32.1 – 88.2(S) 60.1 (S) 0.0- 7.7(S)
32.1 - 
80.3(S)
60.1(S) 232
Switzerland 33,0009 6.5* e 9 1.4 9
United 
Kingdom
139,365-
149,154
3.4-3.7
1.5 f  (England, 
Wales and 
Northern 
Ireland) 
0.55 
(Scotland)10
47.0f  (England, 
Wales and 
Northern Ireland) 
55.0 (Scotland)10
17.0 f g   
(England, 
Wales and 
Northern 
Ireland)10    
7.0h  (S) 
(England)
3.0 (Scotland) 
1.0  (England 
and Wales)
0.5*  
(England 
and Wales)
29.8* 
(England 
and Wales)
42.0* 
(Scotland)
2,368
South Europe
Cyprus 341-642 0.6-1.1 0.0 – 1.6 29.2 – 50.0 0.0 11
France 122,000* 3.2* 5.1 – 8.0 (S) 41.7 (S) 13.3*(S) 53.2-91.0*(S) 333
Greece 6,882-9727 0.9-1.3 0.1 – 0.7 44.9 – 55.5 2.3 – 2.7 63.1* 110
Italy 326,000* 8.34* 11.7 59.2 64.2*(S) 502
Malta 0.0 33.1 7
Portugal 10,950-21,900 1.5-3.0 9.2 – 18.4 33.5 – 84.5 2.7 – 6.1 2.0 28.1*(S) 61.9*(S)
Spain 83,972b* 3.12* 34.5 59.1 – 73.3 (S) 3.0 39.7 89.0 - 91.7* (S) 519
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Country or 
territory
People who 
inject drugs 
Prevalence 
of injecting 
drug use in 
the adult 
population 
(rate per 
1000 in ages 
15-64) 
HIV prevalence 
among people 
who inject drugs 
(%)  
Hep C prevalence 
among people who 
inject drugs  (%) 
Hep B (HBsAg) 
prevalence 
among people 
who inject 
drugs (%) 
Prevalence of 
drug injecting 
among  prisoners 
(%) 
HIV 
prevalence 
among 
prisoners 
who inject 
drugs (%)
Hep C 
prevalence 
among 
prisoners 
who inject 
drugs (%)vii
Hep B 
(HBsAg) 
prevalence 
among 
prisoners 
who inject 
drugs (%)vii
Drug 
related 
deaths
Eastern Europe
Albania
Bosnia-
Herzegovina 
Bulgaria 20,2509 0.4%9 2.2 (S) 57.5 (S) 5.5 (S) 8.0 0.0 17.9 11.6 74
Croatia 2,696-4,148 0.9-1.4 0.0 44.0 0.5 0.0 44.0 0.5 87
Czech 
Republic
30,000-
32,400
4.1-4.4 0.1 – 0.6 11.7 0.4 52.0 44
Estonia
8,132-
3,4443
8.9-37.1 54.3 – 89.9 (S) 89.2 – 90.5 (S) 67
Hungary 2,069-5,813 0.3-0.8 0.0 22.6 0.5 0.2 11.5 (S) 27
Latvia 22.6 (S) 74.4 (S) 10.0 24
Lithuania 5,0009 0.229 0.6 – 9.7 (S) 70.3 – 89.7 (S) 3.3 – 8.9 (S) 60
Macedonia
Montenegro
Poland 9.2 47.3 – 64.0 (S) 1.2 – 8.5 (S) 3.0 214
Romania 17, 767d (S) 11 18 i 11 1.1 60.2 – 65.6 (S) 11.5 (S) 33
Serbia
Slovakia 13,732-34,343 3.5-8.9 1.0 (S) 50 (S)  25
Slovenia 7,320 5.4 0.0 22.3 36
(S) indicate that an estimate is based on sub-national data. * indicates that an estimate is from 2000 or earlier.
a. Figures represent national estimates unless otherwise indicated.  (S) indicate that an estimate is 
based on sub-national data. * indicates that an estimate is from 2000 or earlier.
b. Estimate based on opioid injecting only
c. Estimate includes ever-IDUs and non-IDUs
d. There is no available figure for injecting drug use. This estimate is based on problematic drug use, 
which includes injecting drug use.
e. To standardise the estimated prevalence (%) of IDU among the general population aged 15-64 years 
as reported by Mathers et al. (2008) (0.65%) to the rate per 1000 (6.5), the figures were multiplied 
by 10. 
f. Estimate based on current and former injectors
g. Proportion of hep B antibody positive
h. Estimate based on female prisoners only. 
i. Estimate based on adult population 18-49 years old.
1. European Monitoring Centre on Drugs and Drug Addiction (2010) Statistical Bulletin: Table PDU – 
102 – part ii Injecting Drug Use.
2. European Monitoring Centre on Drugs and Drug Addiction (2010) Statistical Bulletin: Table PDU – 
102 – part ii Injecting Drug Use.
3. European Monitoring Centre on Drugs and Drug Addiction (2010) Statistical Bulletin: Table INF-1.
Prevalence of HIV infection among injecting drug users in the EU, 2008 or most recent year 
available.
4. European Monitoring Centre on Drugs and Drug Addiction (2010) Statistical Bulletin: Table INF-2.
Prevalence of HCV antibody among injecting drug users in the EU, 2008 or most recent year 
available.
5. European Monitoring Centre on Drugs and Drug Addiction (2010) Statistical Bulletin: Table INF-3.
Prevalence of markers for HBV infection among injecting drug users in the EU, 2008 or most recent 
year available.
6. European Monitoring Centre on Drugs and Drug Addiction (2010) Statistical Bulletin: Table DUP-4.
Prevalence of injecting drug use within prison among prisoners, 2000–08.
7. European Monitoring Centre on Drugs and Drug Addiction (2010) Statistical Bulletin:  Table INF-117. 
Prevalence of HIV, HCV and HBV among drug users in prison, 1991 to 2008.
8. European Monitoring Centre on Drugs and Drug Addiction (2010) Statistical Bulletin: Table DRD 1 – 
part ii Numbers of drug-induced deaths and toxicology, 2008 or last year with available information.
9. Mathers, B., L. Degenhardt, et al. (2008). “Global epidemiology of injecting drug use and HIV among 
people who inject drugs: a systematic review.” The Lancet 372(9651): 1733-1745.
10. Health Protection Agency (2010) Shooting Up: Infections among Injecting Drug Users in the UK 
2009: An update: November 2010. London
11. Reitox National Focal Point in Romania (2010) Romania: New Developments, Trends and In-Depth 
Information on Issues of European Interest.2010. National Report to the European Monitoring Centre 
on Drugs and Drug Addiction.
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2.1 Drug use
The use of illicit psychoactive substances in Europe 
is well researched in comparison with most other 
regions of the world. The most commonly used drugs 
are cannabis, cocaine (including crack cocaine and its 
derivatives), ecstasy, amphetamine-type stimulants, and 
opioids (see table 2.2 for more information). Current and 
emerging concerns in the European drug use landscape 
include increasing numbers of cannabis and stimulant 
users seeking treatment, increasingly complex patterns 
of poly-drug use (often including alcohol), and the 
emergent and unique service needs of an aging opioid 
user population.14
Injecting remains a common route of drug-taking 
for both opioids and amphetamines with the largest 
user groups located in Italy, France, Spain, the UK and 
Germany. The largest user groups as a proportion of the 
population are found in Romania, Estonia and Italy (see 
table 2.1 for more information). 
Despite their relative strength, European 
drug use monitoring systems retain a number of 
significant knowledge gaps in areas such as vulnerable 
subpopulations (e.g. migrants, street-involved people 
and young people).  For example, the emphasis on 
school-based surveys for gathering information on young 
people’s drug use omits those outside or excluded from 
mainstream education. Data collection also tends to focus 
on lifetime use or last yearly use of a substance, rather than 
more useful indicators for measuring specifically harmful 
patterns of use.1 Several countries remain heavily reliant 
on service or treatment data which masks the needs of 
those who cannot or do not access these services. The 
absence of clear and accurate drug use data hampers the 
effective targeting of harm reduction programmes.
2.2 Drug-relateD harms
Drug-related harms can be social, economic or 
medical and affect individual users as well as families and 
communities. Among the most serious health-related 
harms are overdose and infectious diseases, particularly 
via injecting drug use. 
Overdose 
Over the past decade Europe has seen between 
6,400 and 8,500 overdose deaths per year.2 In 2007 
Germany and the UK accounted for over half of Europe’s 
reported drug-related deaths,x while the highest drug-
induced mortality rates among 15-64 year olds are found 
in Norway, Estonia, Ireland, Denmark, Finland and the UK 
– all above 40 deaths per million per year.3 Drug-related 
deaths account for approximately 4% of deaths among 
Europeans aged 15-39 years old; opioids are identified in 
three-quarters of these cases.16 A number of risk factors 
have been identified including the mode and prevalence 
of drug use (e.g. opioid use, injection, poly-drug use), age, 
recent periods of detox (including prison sentences), and 
the ability to access health services. WHO-Europe recently 
published recommendations on overdose prevention 
and quality of care in prisons in response to evidence 
showing an increased overdose risk by recently released 
prisoners.4 Non-fatal overdose, which is reportedly 
experienced by most opioid users, increases the risk of 
fatal overdose and is associated with several negative 
health outcomes.5 6 
Improvements in the reliability of European data 
have led to a better understanding of overdose trends, 
and most countries have now adopted a case definition 
in line with the European Monitoring Centre on Drugs 
and Drug Addiction (EMCDDA).7 However, national 
differences in overdose reporting can still hamper inter-
country comparisons.
Infectious diseases
The extent to which HIV, viral hepatitis and 
tuberculosis affect people who inject drugs varies 
dramatically among countries. The significant differences 
in HIV prevalence between Western and Eastern Europe 
have been attributed to a disparity in harm reduction 
responses. For example, early adoption of harm 
reduction measures in the Netherlands, Switzerland and 
the UK have led to a stable and relatively low national HIV 
prevalence among people who inject drugs.8 In contrast 
several Eastern European countries are seeing growing 
epidemics associated with injecting drug use, often with 
co-infections of HIV, hepatitis C and/or TB.18
There is a lack of data on the impact of infectious 
diseases on prisoners in Europe, but alarming rates of HIV 
in Southern European prisons and hepatitis C prevalence 
in numerous prison populations point to an urgent need 
for action (see table 2.1 for more details).
x  The EMCDDA definition of drug-induced deaths or drug-related deaths 
refers to 'people who die directly due to use of illegal substances, although 
these often occur in combination with other substances such as alcohol 
or psychoactive medicines. These deaths occur generally shortly after the 
consumption of the substance.' 
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2.3 summary of finDings: harm 
reDuction responses, barriers 
anD civil society aDvocacy 
priorities
Coverage of harm reduction programmes 
Thirty-six countries in the region are known to 
implement NSPs and OST, with five also providing heroin-
assisted treatment (HAT).20 Five countries have NSPs and 
23 offer OST in prisons and other places of detention. 
However, provision of harm reduction services in these 
settings continues to lag behind provision in the wider 
community, especially in South and Eastern Europe (see 
section 3 for more details). 
Europe is home to the largest number of drug 
consumption rooms (DCRs) in the world. Approximately 
60 are in operation in 36 European cities, mostly in 
North Europe.xi 9 The introduction of DCRs in most of 
Eastern Europe faces significant political opposition, 
with most CSOs in that region still advocating for the 
implementation and expansion of the most basic harm 
reduction interventions. 
Barriers to NSPs in Europe include limited or 
nonexistent coverage outside major cities, restricted 
opening hours, and admission criteria such as age 
restrictions.10 In Eastern Europe additional barriers include 
fear of police harassment and arrest, perceived stigma, 
lack of secure funding and political opposition.21 Access 
to OST is similarly restricted by lengthy waiting lists, strict 
admission criteria, and a lack of national evidence-based 
standards for OST provision and quality of care. Across 
xi  Two pilot projects of medically supervised injecting centres also 
operate in Australia and Canada.
Europe the populations at greatest risk of exclusion from 
harm reduction services are women, young people and 
migrants.21
HIV, viral hepatitis and tuberculosis services
In November 2010 the EMCDDA reported that 
uptake of HIV, viral hepatitis and tuberculosis testing 
remains low in many European countries, and released 
a set of guidelines for testing for blood-borne infections 
among people who inject drugs.11 According to CSOs in 
Europe the requirement to be drug-free as a prerequisite 
for access to treatment presents a significant barrier 
to take-up of testing and treatment services for HIV, 
hepatitis C and TB.21 The cost of HCV treatment remains 
prohibitive for some subpopulations such as migrants, 
as do limited integration of services and weak referral 
systems, particularly outside of major cities.21 A highly 
effective integrated response to HIV, hepatitis and 
tuberculosis responses, including prevention, diagnosis 
and treatment services, is recommended by several 
international agenciesxii for people who use drugs both in 
the community and in prison.5 8 12 
Overdose responses
Naloxone is a highly effective, side-effect free 
intervention for the prevention and management of 
overdose, but availability is poor and peer-distribution 
remains controversial.xiii 13 14 Peer distribution of naloxone 
xii  The package and recommendations were developed by WHO, 
UNODC in 2009 and have since been enshrined in the political declaration 
and plan of action of the Commission on Narcotic Drugs (CND) and an 
ECOSOC resolution in 2009.
xiii  Naloxone reverses the effects of opioids (including heroin), 
particularly the respiratory depression that leads to death in case of 
overdose. 
Table 2.2: Drug use in Europe14
Substance Last year use Last month use
Cannabis
about 23 million European adults (6.8 %) or
a third of lifetime users
about 12.5 million Europeans (3.7 %)
Cocaine
4 million European adults (1.3 %) or
a third of lifetime users
around 2 million (0.5 %)
Ecstasy
about 2.5 million (0.8 %) or
a quarter of lifetime users
nk
Amphetamines
around 2 million (0.6 %) or
a sixth of lifetime users
nk
Opioids
People who use opioids ‘problematically’: estimated at 
between 1.2 and 1.5 million Europeans
Principal drug in more than 50 % of all drug 
treatment requests
About 670 000 opioid users received substitution 
treatment in 2008
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can bypass barriers to formal medical care, such as fear 
of arrest and discrimination.9 27 Peer distribution of 
naloxone is reported only in Spain, Denmark, Italy and to 
a limited extent, France and the United Kingdom. In most 
countries in the region naloxone is only authorised for 
use by medical staff in emergency units. 
Harm reduction in recreational settings
Amphetamine-type stimulants (ATS) are reported 
to be widely used by young people aged 15–34 years 
in recreational settings across the region, but there is 
a lack of disaggregated data to distinguish between 
recreational use and more problematic patterns.15  Pill 
testing, particularly on-site within nightlife settings, 
has been employed to detect adulterants and new 
synthetic drugs, thereby reducing potential harms.16 This 
intervention remains controversial and has been reported 
to be “steadily less common in Europe.”40  The majority 
of programmes related to recreational drug use remain 
unevaluated, and few syntheses of evidence addressing 
young people’s recreational use have been conducted 
to date. 15 40 Interventions such as outreach, counselling, 
and information, education and communication (IEC) 
materials are provided by CSOs in a majority of countries 
in North and South Europe and nearly half of Eastern 
European countries.  Pill testing is implemented to varying 
degrees in Austria, Germany, Switzerland, Denmark, 
Norway, Spain and the Netherlands.21
Drug user involvement in harm reduction 
responses
Meaningful involvement of people who use 
drugs in service design, implementation, monitoring 
and evaluation is generally scarce across Europe. 
Levels of engagement are assessed using the “pyramid 
of involvement” model which outlines a range of 
increasingly-involved roles for people who use drugs 
from passive target audiences to tokenistic speakers 
or representatives, and finally to equal participants 
in decision-making bodies. 17 Three forms of user 
involvement have been described: individual-level 
involvement in the work of CSOs; organisational-level 
involvement in the form of participation in consultations, 
decision-making and policy-making bodies; and drug 
user organising around autonomous groups who work 
toward self-determined agendas. 
In most countries in Europe user representation 
occurs at individual and program levels only. 
Representation is generally tokenistic or consultative, 
with former and occasionally active users engaging 
with services as peer educators, NSP assistants, outreach 
workers and other “gatekeepers.”  In the Netherlands, 
where user-led groups pioneered harm reduction 
initiatives in the 1970s, CSOs report that most user-led 
initiatives are dormant or no longer directly involved in 
service development.18 
Across the region, barriers to participation 
include the limited capacity of the few existing user-run 
organisations to engage in advocacy, the criminalisation 
of drug possession, and the high levels of perceived 
stigma against people who use drugs.4 CSOs across 
Europe have highlighted the need to consolidate and 
strengthen existing user groups, raise public awareness 
and exchange best practices around effective and 
meaningful user involvement in service design, 
implementation, monitoring and evaluation.4
2.4. emerging aDvocacy issues for 
europe 
Despite long-standing support for harm reduction 
in parts of Europe, this regional consensus is under threat 
from political changes, financial hardship and a growing 
emphasis on abstinence-based treatment and supply 
reduction. While there is widespread acceptance of 
NSPs and OST across Europe, other interventions remain 
controversial. These include DCRs, HAT and prison-based 
NSPs, as well as innovative responses to overdose and 
drug use in recreational settings, particularly in South 
and Eastern Europe. There is an urgent need to scale up 
access to harm reduction services and to integrate them 
into existing services including primary healthcare, low-
threshold service centres, sexually transmitted infections 
(STIs) clinics and prison healthcare facilities.xiv 
Although most countries in Europe make explicit 
reference to harm reduction in their national policy 
documents,19 this does not imply consistent financial 
support. International funds, largely via The Global 
Fund, have supported the scale-up of service provision 
across Eastern Europe in the past decade and remains 
the major funder for harm reduction in the region. 
Between 2003 and 2009, The Global Fund has provided 
over $29.9 million for harm reduction in 7 countries. The 
principal challenge to harm reduction programmes in 
Eastern Europe is the unwillingness of many national 
governments to supplement service provision needs 
if countries become ineligible for international funds 
xiv  New EMCDDA guidelines recommend that health providers initiate 
examination, testing and counselling in IDUs in a variety of healthcare 
settings including primary healthcare, low-threshold service centres, 
rehabilitation centres, sexually transmitted infections (STIs) clinics and 
prison healthcare facilities. 
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and other international contracts.21 In other countries 
where national governments co-finance harm reduction 
programmes CSOs have reported that this support is 
insufficient to scale-up service coverage adequately. 
Finally, it is important that services which have 
made an impact on epidemics in North and South Europe 
are sustained and supported to deliver effective HIV, 
viral hepatitis and TB prevention, treatment and care. 
The sustainability and scale up of evidence - and human 
rights-based harm reduction interventions in the face of 
financial austerity and cuts to services is a challenge that 
will require a concerted effort from stakeholders across 
the region. Without these efforts the gains made by harm 
reduction in Europe could be lost.
a key outcome of the audit was to identify advocacy 
priorities for each of the european sub-regions. in 
addition to this, several cross-cutting priorities for 
advocacy emerged across the european region:
  Scale up evidence-based harm reduction 
services such as NSPs and OST, particularly 
outside of major cities, and in prisons and 
other places of detention
  Remove barriers to harm reduction service 
access, particularly for the most marginalised 
groups including young people, illegal 
migrants and women
  Effectively integrate testing and treatment 
services for HIV and AIDS, viral hepatitis and 
tuberculosis within drug treatment services
  Expand availability and peer access to 
naloxone for overdose prevention 
  Challenge stigma and discrimination against 
people who use drugs
Within each of the sub-regions, civil society 
organisations identified advocacy priorities 
particularly relevant to each regional context:
eastern europe 
  Ensure adequate and secure funding for 
harm reduction programmes from national 
governments 
  Reorient drug policies to reflect evidence-
based public health and human rights-based 
approaches, including decriminalising drug 
use for personal possession
  Implement evidence-based harm reduction 
services, particularly NSPs, and scale up 
provision of OST in prisons and other places 
of detention 
  Scale up provision of current NSP and OST 
programmes in the community
north europe 
  Ensure that adequate harm reduction services 
remain part of national policy agendas
  Increase access to social support and 
housing services for people who use drugs
  Improve integration of testing and treatment 
services for HIV, viral hepatitis and 
tuberculosis
  Develop existing civil society networks for 
people who use drugs
south europe 
  Implement evidence-based harm reduction 
services, particularly NSPs, and scale up 
provision of OST in prisons and other places 
of detention 
  Implement and scale-up drug consumption 
rooms (DCRs)
  Increase integration of harm reduction 
interventions, including overdose prevention 
programs and safer nightlife initiatives, testing 
and treatment services for HIV, viral hepatitis 
and tuberculosis within national public health 
goals
  Improve the meaningful involvement of people 
who use drugs in service design, provision, 
monitoring and evaluation.
civil society aDvocacy priorities
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3.1 EASTErn 
EUrOPE
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   
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   
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    Finland  
Sweden
  
Denmark
  
Germany
    Netherlands
   
Belgium
  
Luxembourg
    
Switzerland
  
Austria
  
Needle and syringe exchange
Opioid substitution therapy
Drug consumption rooms
Prison needle exchange programme
Prison opioid substitution therapy
AlbAniA
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bulgAriA
CroAtiA
CzeCH republiC
estoniA
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lAtviA
litHuAniA
MACedoniA
Montenegro
polAnd
roMAniA
serbiA
slovAkiA
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   
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
Czech Republic
   
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   
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   
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
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   
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   
Availability of harm reduction interventions in eastern europe
22
table 3.1.1: Availability and coverage of harm reduction interventions in eastern europe 
Country Or 
Territory
Needle ANd SyriNge exChANge PrOgrAmme OPiOid SubSTiTuTiON TherAPy
drug 
Consumption 
rooms1 
Prison Needle 
exchange 
Programme 
existence2 and 
Availability3
Prison Opioid 
Substitution 
Treatment
Availability,a 4 
initiation (i)  and 
Continuation (C)5
Availability, 
Syringe 
Vending 
machine (S), 
And Pharmacy 
based NSP (P)6
Number of 
sites7
Syringes 
distributed 
annually through 
specialised 
sites per person 
injecting drugs b 8
Availability and 
form c 9 
Number 
of sites 10
% opioid 
users 
receiving 
OST 11 
Albania 3 1 No
Bosnia-
Herzegovina
6 6-8 No
Bulgaria Yes 100 Yes (M, BN, SM) 17 No No Yes (C)
Croatia Yes (P) 42 79 (62 – 95) Yes (M, B) No No
Czech Republic Yes 109 149 (143 – 155) Yes (M, B, BN) 47 35 (33 – 38) No No
Yes, limited 
(I, C)
Estonia Yes 36 144 (58 – 246) Yes (M, Bd ) 8 No No Yes (C)
Hungary Yes (S) 25 76 (51 – 144) Yes (M, BN) 13 No No Yes, rare (I, C)
Latvia Yes 13-22 18 (13 – 26) Yes (M, B) 1-9 No No No
Lithuania Yes 10-19 Yes (M, B) 14-18 9 (9 – 9) No No No
Macedonia 15 9 No
Montenegro 18 No
Poland Yes 27 Yes (M, BN) 22 6 (5 – 6) No No Yes, rare (C)
Romania Yes 49 Yes (M, B, BN) 6-8 No Yes, rare Yes (I, C)
Serbia 13 14 No
Slovakia Yes (P) 20 14 (7 – 19) Yes (M, Be, BN, SM) 12 5 (3 – 7) No No No 
Slovenia Yes 17 Yes (M, B, BN, SM) 20 No No Yes, full (I, C)
a.     Full: substitution/maintenance treatment exists in nearly all prisons 
Extensive: exists in a majority of prisons but not in nearly all of them 
Limited: exists in more than a few prisons but not in a majority of them 
Rare: exists in just a few prisons
b.     Data is from 2008 or most recent year available.
c.      M = methadone; B = High-dosage buprenorphine; H = Heroin assisted treatment; 
BN = Buprenorphine-naloxone combination;  SM = Slow-release morphine.
d.     Legally available but no reported clients.
e.     Legally available but no reported clients.
1. European Monitoring Centre on Drugs and Drug Addiction (2010) Drug 
consumption facilities in Europe and beyond, in Harm Reduction Monograph: 
Harm reduction: evidence, impacts and challenges.
2. European Monitoring Centre on Drugs and Drug Addiction (2010) Statistical 
Bulletin: Table HSR4. Year of introduction of needle and syringe programmes 
(NSPs) and types of programmes available in 2008.
3. European Monitoring Centre on Drugs and Drug Addiction (2009) Statistical 
Bulletin: Table HSR-7. Availability and level of provision of selected health 
responses to prisoners in 26 EU countries, Norway and Turkey (expert ratings).
4. European Monitoring Centre on Drugs and Drug Addiction (2009) Statistical 
Bulletin: Figure HSR-2. Provision of substitution/maintenance treatment (OST) in 
the community and availability of OST programmes in the prison.
5. European Monitoring Centre on Drugs and Drug Addiction (2010) Statistical 
Bulletin: Table HSR9. Opioid substitution treatment in prison in EU 27, Croatia, 
Turkey and Norway.
6. European Monitoring Centre on Drugs and Drug Addiction (2010) Statistical 
Bulletin: Table HSR4. Year of introduction of needle and syringe programmes 
(NSPs) and types of programmes available in 2008.
7. Mathers B et al (2010) HIV prevention, treatment and care for people who inject 
drugs: A systematic review of global, regional and country level coverage. Lancet 
375 (9719):1014-28.
8. European Monitoring Centre on Drugs and Drug Addiction (2010) Statistical 
Bulletin: Figure HSR-3. Syringes distributed through specialised programmes per 
estimated IDU in 2008 or more recent year.
9. European Monitoring Centre on Drugs and Drug Addiction (2010) Statistical 
Bulletin: Table HSR1. Table HSR-1. Year of introduction of methadone maintenance 
treatment (MMT), high-dosage buprenorphine treatment (HDBT), buprenorphine/
naloxone combination, heroin-assisted treatment and slow-release morphine 
10. Mathers B et al (2010) HIV prevention, treatment and care for people who inject 
drugs: A systematic review of global, regional and country level coverage. Lancet 
375 (9719):1014-28.
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Harm reduction in eastern europe
the authors would like to acknowledge the contributions of the 
following organisations in providing information for their respective 
countries:a 
stop Aids Association (Albania), Association Margina (bosnia-
Herzegovina), initiative for Health Foundation (bulgaria), udruga 
terra (Croatia), sananim (Czech republic), Convictus eesti (estonia), 
the Hungarian Civil liberties union (Hungary), labyrinth (kosovo), 
dialogs (latvia), Coalition i CAn live (lithuania), Healthy options 
project skopje (Macedonia), Juventas (Montenegro), polish drug 
policy network (poland), romanian Harm reduction network 
(romania), veza (serbia), odyseus (slovakia), stigma (slovenia)
Across Eastern Europe, harm reduction approaches have become increasingly accepted and recognised in practice and at the policy level. 
Although harm reduction is explicitly mentioned as 
part of national health, drugs or HIV/AIDS strategies in 
all countries except Montenegro, service provision is 
overwhelmingly supported by international donors, 
particularly in non-EU member countries. NSP and 
OST service coverage varies widely among and within 
countries, remaining low in most countries for which 
data is available. There is no DCR or HAT provision in the 
region. 
Harm reduction interventions are yet to be widely 
scaled up and adequately financed. Limited integration 
and coordination among low threshold drug services and 
HIV, viral hepatitis and tuberculosis testing and treatment 
remains a challenge in the majority of countries. 
Availability of harm reduction services in prisons and other 
closed settings is scarce and many programs remain in 
the pilot stage. Prison OST is provided in seven countries 
in the region, while NSPs are only available in five prisons 
in Romania. Naloxone for overdose prevention and 
management is available largely through emergency care 
units, but distribution is not permitted through peers or 
through harm reduction services such as NSPs and OST. 
Harm reduction interventions in recreational settings 
are limited to the provision of information, education 
and communication (IEC) materials, campaigns and 
peer outreach and are implemented in nearly half of the 
countries in Eastern Europe. 
Across the region, meaningful drug user 
representation in service design, implementation, 
a  Questionnaire responses from Latvia, Serbia and Slovenia were not 
available at the time of writing. 
monitoring and evaluation occurs mostly at the 
programmatic rather than the organisational or policy 
levels. 
Continued civil society advocacy is crucial for 
increasing concrete support for harm reduction from 
national governments across Eastern to supplement 
the significant gap expected to emerge once countries 
become ineligible for international funds.
Civil SOCiETy OrgAniSATiOnS hAvE idEnTifiEd 
SEvErAl AdvOCACy PriOriTiES fOr ThiS 
rEgiOn. ThESE inClUdE:
  Ensure adequate, predictable funding for 
harm reduction programmes from national 
governmentsb
  Reorient drug policies to reflect evidence-
based public health and human rights-based 
approaches, including decriminalising drug use 
for personal possessionc
  Implement evidence-based harm reduction 
services, particularly NSPs, and scale up provision 
of OST, in prisons and other places of detentiond
  Scale up provision of current NSP and OST 
programmes in the community.e
nEEdlE And SyringE ExChAngE 
PrOgrAmmES (nSPs)
NSP sites operate in each of the seventeen countries 
and territories that comprise the Eastern Europe region 
(see table 3.1.1). Distribution of sterile injecting equipment 
is largely through fixed and mobile sites, including 
distribution through mobile vans and outreach workers. 
The only exceptions are Croatia and Slovakia, which also 
dispense syringes through pharmacy-based NSPs, and 
Hungary, which operates one syringe vending machine.1 
NSP service provision varies widely across the region 
from ten or fewer operational sites in Albania, Bosnia-
b Bulgaria, Croatia, Lithuania, Macedonia, Romania, Slovakia.
c Albania, Bosnia-Herzegovina, Macedonia, Montenegro, Romania.  
d Bulgaria, Lithuania, Czech Republic.
e Kosovo, Romania, Slovakia.
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Herzegovina and Kosovo,2 to 100 or more sites in Bulgaria 
and the Czech Republic.3 Among the six countries where 
data exists, service coverage ranges from low in Croatia, 
Hungary, Latvia and Slovakia to medium in the Czech 
Republic and Estonia.f Data on the number of needles/
syringes distributed per person injecting drugs per year is 
unknown for eleven countries in the region.1
Service provision varies within countries, and is 
particularly limited outside of major cities in Albania, 
Bulgaria, Croatia, Estonia, Kosovo, Lithuania, Macedonia, 
Montenegro, Romania and Slovakia.4 The only exception is 
the Czech Republic, where NSP services are well-established 
across the country.5 In Albania, Montenegro and Romania 
operational NSPs are only found in Tirana, Podgorica and 
Bucharest respectively, although some mobile units based 
in Podgorica also operate outside of the capital.4 A newly-
operational NSP site in Timisoara, Romania established in 
2008 was recently closed after contact with the community 
of people who inject drugs was lost.6 
Several factors limit the quality and effectiveness of 
existing NSP services in the region. Fear of police harassment 
and arrest was cited as an important barrier to service access 
for people who use drugs, particularly in Albania, Bosnia-
Herzegovina, Bulgaria, Hungary and Romania.4 In Croatia, 
syringes are available for purchase at pharmacies, but some 
pharmacists in rural areas refuse to sell needles and syringes 
to people who use drugs.7 Discrimination by medical workers 
was cited as a barrier to service access in Montenegro, where 
the only operational NSP site is integrated within primary 
health services.8 Political resistance and lack of predictable, 
long-term funding pose significant obstacles to sustaining 
current coverage levels and scaling up NSP services across 
the region.g 4 
The absence of professional standards for harm 
reduction service workers,9 incomplete national data on 
drug use,6 lack of indicators for monitoring service quality 
and effectiveness9 and lack of gender-focused programs10 
further limit the reach and quality of existing services. NSP 
services remain stigmatised among the general public 
in a majority of countries in Eastern Europe.h 4 Sustained 
advocacy efforts are required to increase tolerance for this 
intervention at the local level. 
f  According to the WHO, UNAIDS and UNODC target-setting guide 
(2009), low NSP coverage is £100 needles/syringes distributed per 
injector per year, medium coverage is >100–£ 200 needles/syringes 
distributed per injector per year and high coverage is >200 needles/
syringes distributed per injector per year. Due to the difficulties in 
determining the size of the population who inject drugs and NSP 
monitoring data, these estimates should be interpreted with caution. 
g  In Croatia and Slovakia, the government financially supports NSP 
services, but unpredictable funding threatens the sustainability of 
services. 
h  Kosovo, Bosnia-Herzegovina, Montenegro, Romania, Estonia, Slovakia, 
Lithuania, Hungary.
nEw drUgS: AdvOCATing fOr 
EvidEnCE-bASEd dECiSiOn-
mAking in rOmAniA
valentin Simionov
The ‘smart drugs’ market in Romania first began 
to expand in 2007. Increasingly more synthetic drugs, 
largely cannabinoids, cathinones, piperazines and 
stimulants, have since been marketed online and 
subsequently in local ‘smart shops’ as air fresheners or 
bath salts. Reliable figures and data prevalence of use 
are not available.  
Dramatic media coverage of hospitalizations 
attributed to new drugs and pressure from a reactive 
public pressed the government to implement strict 
measures to prohibit new drug production, distribution 
and consumption. In February 2010, the Government 
amended the legislation on controlled substances, 
initially adding 36 psychotropic plants and substances 
to the controlled substances list, and including 
another 6 shortly after. These measures had limited 
or no impact on the market. Retailers introduced new 
substances, which were not prohibited by the law, and 
increasingly more injecting heroin injectors switched 
to injecting synthetic stimulants due to their wider 
availability and legal status. 
Further measures were taken in February 
2011 with the government initiating a consultation 
at the ministry level, also involving civil society 
representatives. ’Control teams’ were formed within 
the Ministry of Interior, Ministry of Health, Ministry 
of Finance, Ministry of Agriculture and the Office 
for Consumers Protection with the aim of reporting 
monthly on the new drugs situation. A growing 
number of municipalities have restricted selling 
licensing criteria with the aim of shutting down ‘smart 
shops’. In some counties, for instance, smart shops 
cannot operate less than 2 km far from schools. 
The Romanian Harm Reduction Network and 
partner organizations have argued against shutting 
down smart shops based on EU regulations on the 
free movement of merchandise within the EU territory. 
Human rights concerns have also emerged around the 
illegal processing of personal information from users 
by some municipalities in Bucharest. Civil society 
organizations in Romania continue to advocate for 
informed decision-making, emphasizing that control 
measures on new drugs must be based on evidence 
rather than public and media pressure. 
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OPiOid SUbSTiTUTiOn ThErAPy (OST)
All countries in Eastern Europe implement some 
form of OST (see table 3.1.1). Methadone maintenance 
therapy (MMT) is available in fourteen countries in the 
region.11 Additional forms of OST, such as high-dosage 
buprenorphine (BMT) are available in ten countries,12 
buprenorphine-naloxone combination in seven 
countries, and slow-release morphine in three countries.13
Service provision varies across the region, from less 
than 10 sites in Albania, Bosnia-Herzegovina, Estonia, 
Latvia, Macedonia, and Romania to between 10 and 20 
sites in Bulgaria, Hungary, Lithuania, Serbia, Slovakia 
and Slovenia.3 The exceptions are Poland, where 22 sites 
provide OST for 6 (range 5-6) per cent of opioid users, 
and the Czech Republic, where 47 sites3 provide OST for 
35 (range 33-38) per cent of opioid users in the country.14 
Service coverage data (percent of opioid users receiving 
OST) are unavailable for the majority of countries in the 
region. 
There are several challenges to OST access and 
provision in most countries. i 4  Service access is restricted 
by fear of stigma,j long waiting lists,k age restrictionsl and 
a lack of evidence based standards for OST provision and 
quality of care, particularly for women who use drugs.15 
In Hungary, Macedonia and Montenegro, reported 
shortages of trained medical professionals willing to staff 
drug services further limits OST scale up, as well as the 
quality of existing services.4 In Bulgaria and Montenegro, 
fees for accessing OST are reported to deter some people 
who use drugs from accessing the service. The few free 
OST programs that are implemented in Bulgaria prioritise 
people who use drugs living with HIV and pregnant 
women.15 Start up of OST in Kosovo was pending approval 
from the Ministry of Health at the time of publication, 
with waiting lists already in existence. However, rollout is 
not expected until 2012.2
Across the region, lack of political support and 
limited state funding for OST is a barrier to service quality 
and scale up.m  There is an urgent need to strengthen 
advocacy efforts with national and local governments in 
the region. 
i  Albania, Czech Republic, Hungary, Bulgaria, Lithuania, Slovakia, Estonia, 
Romania, Montenegro, Macedonia, Bosnia-Herzegovina,  Albania.
j  Lithuania, Macedonia, Montenegro.
k Montenegro, Romania, Albania, Kosovo.
l  Estonia, Montenegro and Romania.
m    Particularly in Albania, Czech Republic, Hungary, Kosovo, Lithuania and 
Romania. 
drUg COnSUmPTiOn rOOmS (dCrs)
There are no countries in Eastern Europe that 
implement DCRs.
Across the region, legal and political barriers 
and lack of sustainable funding for existing harm 
reduction interventions such as NSPs and OST mean 
that implementation of DCRs remains controversial. The 
Czech Republic is the only country in the region where 
implementation of DCRs was reported to be a concrete 
advocacy priority for civil society.
hiv, virAl hEPATiTiS And 
TUbErCUlOSiS (Tb) SErviCES
HIV testing and treatment services
Free, universal access to voluntary counseling and 
testing (VCT) and antiretroviral treatment (ART), including 
for people who use drugs, is reported to be widely 
available in Bosnia and Macedonia.4 However, across the 
region, access and take up of HIV testing and treatment 
services are restricted by several factors. Barriers include 
limited awareness among people who use drugs about 
the availability of testing sites,n confidentiality concerns 
around the disclosure of test results,o restricted hours 
of operation at existing testing facilities,p insufficient 
availability/provision of testing servicesq and stigma 
associated with a positive HIV test result.r 4 In Albania, the 
lack of rapid finger-prick or saliva tests for HIV is reported 
to deter some people who inject drugs that may have vein 
problems from seeking a test.16 Although VCT is provided 
at a cost in public health care centres in Romania, free 
access to VCT is only available in the community through 
NGOs in Bucharest and within prisons.6 Provision of 
VCT by CSOs and outreach teams remains controversial 
in Slovakia and Estonia, where there remains a need to 
further diversify means of provision.4
Data on the extent of ART coverage among people 
who inject drugs (i.e. numbers and ratios of people who 
inject drugs living with HIV that are receiving ART) are 
largely unknown for most countries in the region.17 ART 
is free to all people who use drugs that are living with 
HIV irrespective of drug use status in Croatia,18 Hungary,19 
n  Bulgaria.
o  Croatia.
p  In Slovakia, for instance, The National Reference Centre offers VCT 
services over two hours for two days a week, and there are only two 
NGOs in the country that offer this service. 
q  Kosovo. Hungary. For instance, Hungary implements occasional HIV 
testing campaigns, but there is no permanent availability of VCT 
testing services at fixed sites.
r  Kosovo.
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Serbia, Bosnia, Kosovo, Macedonia and Romania. However, 
the extent of service take-up is unknown.4 In some 
countries in the region, barriers to ART access for people 
who use drugs are posed by complex administrative 
procedures from diagnosis to treatment start-up,s and 
stigma and discrimination against people who use drugs 
that are living with HIV by health care workers and GPs.t 4 
Viral hepatitis testing and treatment 
services
Among countries where data is available, only 
Romania, Slovenia and Slovakia implement hepatitis B 
vaccination programmes targeted at high-risk groups 
including people who use drugs.20 HBV vaccination 
programs in prisons are implemented in Estonia, 
Lithuania and Slovenia.27 
In several countries across the region,u eligibility 
criteria that includes abstinence for several months prior 
to commencing Hepatitis C (HCV) treatment poses an 
obstacle to access for people actively injecting drugs.4 
In Serbia, people who use drugs must be abstinent 
for one year prior to starting treatment.21 Treatment is 
also inaccessible to people who use drugs that do have 
health insurance in Bulgaria and Slovakia.4  Additional 
barriers cited by CSOs across the region include limited 
HCV testing options (i.e. using rapid tests),v weak national 
surveillance systems for HBV and HCV among people who 
inject drugs,w inadequate knowledge of the transmission 
modes and risks associated with HCV among people 
who use drugs,x lack of funding for HCV as compared 
with resources for HIV prevention and treatment,y 
high treatment costs,z stigma associated with an HCV 
diagnosisaa and weak referral systems between GPs and 
drug services.ab 
Tuberculosis testing and treatment services
Barriers to TB testing and treatment access among 
people who use drugs were reported in some countries 
in the region. These include weak referral systems,ac 
eligibility criteria for accessing treatmentad and limited 
s  Bulgaria
t  Slovakia.
u Albania, Bulgaria, Hungary, Macedonia, Montenegro, Romania, Slovakia 
and Serbia.
v  Croatia.
w Estonia.
x  Kosovo.
y  Kosovo.
z  Macedonia.
aa   Montenegro.
ab   Montenegro, Romania. 
ac    Kosovo, Romania.
ad   Slovakia.
coordination between drug services and other health 
institutionsae as well as between government and CSOs.af 
People who use drugs in Romania are not included in 
routine TB testing or in national data collection on TB 
prevalence.6 In Slovakia, the NGO Odyseus has recently 
introduced low threshold HIV/TB testing for marginalized 
groups, including migrants who use drugs through its 
outreach work.ag
Strong referral systems among HIV, HCV and TB 
services were reported in Albania, Bosnia, Bulgaria, 
Croatia, Czech Republic, Hungary and Macedonia.4
hArm rEdUCTiOn in PriSOnS
Availability of harm reduction interventions in 
prisons is very limited across Eastern Europe (see table 
3.1.1). Romania is the only country in the region that 
implements NSPs in five prisons with technical and 
financial support from UNODC.22 
Prison OST is confirmed in seven countries, but 
service coverage varies widely among and within 
countries.23 Some degree of provision is reported in 
prisons in Croatia7 and pre-detention trial units in Albania, 
although OST is not available as an integral part of health 
services in Albanian prisons.16
The Czech Republic, Hungary, Romania and 
Slovenia provide initiation and continuation of OST in 
prisons to varying degrees (see table 3.1.1).24 Continuation 
of OST in prison is available in Bulgaria, Estonia, Poland 
and Montenegro8 if the inmate was already enrolled in 
OST prior to arrest.23 MMT start up in Kosovo prisons is 
planned to begin after 2011.
Barriers to implementation and scale up of harm 
reduction interventions in prisons include lack of political 
will,ah denial of the existence of drug use in prisons,ai 
shortages of staff for medical services within prisons,aj 
lack of funding and data gaps on the extent of drug use in 
prisons across the region. ak 4 
ae   Albania.
af    Bosnia.
ag   From September 2010 to August 2012 the Slovakian NGO Odyseus 
implements "Imp.Ac.T: Improving Access to HIV/TB testing for 
marginalized groups”, a project supported by European Commission, 
which aims to broaden access to HIV and TB testing, prevention, 
treatment and care for people who inject drugs and migrants who use 
drugs in Slovakia, Czech Republic and Italy.
ah   Bulgaria, Croatia, Czech Republic, Hungary, Lithuania, Macedonia.
ai    Bulgaria, Slovakia.
aj    Bosnia-Herzegovina, Croatia, Slovakia.
ak    Romania. 
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OvErdOSE rESPOnSES
For most countries where data is available, overdose 
prevention responses include limited or rare provision of 
overdose information material to people who use drugs, 
individual overdose risk assessment, overdose response 
trainingal and risk education on drug-related deaths.25 In 
the Czech Republic, Lithuania and Slovenia, provision and 
reach of overdose prevention responses is reported to be 
extensive.am
The availability of naloxone remains very limited 
in most countries across Eastern Europe. However, 
systematic data on the coverage of this intervention is 
not known. Naloxone is not provided at all in Albania, 
but it is available to varying degrees through emergency 
care units in all other countries for which information is 
available.4 Across the region, naloxone distribution is 
not permitted through peers or through harm reduction 
services such as NSPs and OST.4 Peer distribution of 
naloxone is presently being considered in Estonia.9 
Barriers to the implementation and scale-up 
of effective overdose responses, including naloxone 
provision, include laws limiting management and 
transportability of naloxone by non-medical personnel, 
delays in the provision of emergency care responses 
for overdosean and shortages of naloxone in emergency 
units.ao 4 There is an urgent need for advocacy around 
scaling up the distribution of naloxone beyond medical 
services to harm reduction programmes, outreach 
workers and people who use drugs, their families and 
communities. 
hArm rEdUCTiOn fOr rECrEATiOnAl 
drUg USE 
Harm reduction interventions in recreational 
settings, including information, education and 
communication (IEC) materials, campaigns and peer 
outreach, are implemented in nearly half of the countries 
in the region.ap 4 Initiatives in Bosnia-Herzegovina 
and Slovakia also provide counselling, condoms and 
information about sexually transmitted infections (STIs) 
al    According to the EMCDDA (2010) (2) Overdose response training 
is defined as: One-to-one or group education sessions on risks, 
prevention of risks and on management of overdoses. This training 
should include: information on risk situations and risky behaviour, how 
to recognise overdoses, and how to respond adequately (at least the 
recovery position).
am  ‘Extensive’ is defined by the EMCDDA (2010) “a majority of the target 
group (but not nearly all of them) have received the service during the 
last year at least once.”
an   Bulgaria.
ao   Macedonia. 
ap   Bosnia-Herzegovina, Macedonia, Bulgaria, Croatia, Czech Republic, 
Hungary, Lithuania and Slovakia.
including HIV.4 Pill testing in recreational settings is not 
offered in any countries in the Eastern Europe region.
Implementation and scale up of harm reduction 
interventions in recreational settings across Eastern 
Europe is limited by several factors. These include a lack of 
systematic data on prevalence and trends in recreational 
drug use and existing harm reduction responses and 
minimal or no funding for such initiatives across the 
region.4 In Hungary, resistance from a majority of 
nightclub owners limits coverage of existing initiatives.26 
POliCy SUPPOrT fOr hArm 
rEdUCTiOn
Harm reduction is explicitly mentioned within 
national health, drugs or HIV/AIDS strategies of most 
countries that comprise the Eastern Europe region. 
However, in many states in the region, this support is 
largely ‘on paper’ only.  In August 2011, Hungary adopted 
a new drug strategy focused strongly on abstinence-
based approaches, and slashed the country’s drug 
budget by 50%; the strategy was in the process of being 
finalised at the time of publication.27 30  
Funding for harm reduction responses in Eastern 
Europe comes largely from The Global Fund.27 The 
top three largest recipients in the region are Bosnia-
Herzegovina, Macedonia and Serbia.28 Other donors 
that support harm reduction in Eastern Europe include 
the European Commission, UNODC, OSF, UNICEF and 
PSI.4 Additional funding for harm reduction service 
provision is provided by national governments in Estonia, 
Montenegro, Bulgaria, Hungary, Croatia, Czech Republic, 
Lithuania and Slovakia. However, in some countries, 
government funds for harm reduction are reported to be 
insecure and insufficient to sustain and scale up the level 
of service coverage required to have an impact on HIV 
and viral hepatitis epidemics.aq 4 29 In Bulgaria and Serbia, 
state funding supports MMT programmes, but not NSPs.4 
 In Montenegro, a state grant was utilised to open 
the first drop-in center for people who use drugs, but at 
the time of publication all harm reduction services in the 
country were financed by The Global Fund.31
In the past decade, the influx of funds from 
international donors has supported and encouraged 
scale up of service provision across the region. However, 
there is considerable concern around the willingness 
of some national governments to supplement service 
needs once countries become ineligible for The Global 
Fund funds and other international contracts expire.  A 
case in point is Romania, where in June 2010, programs 
aq  Croatia, Lithuania, Slovakia. 
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developed with international donor support over the 
previous ten years were left without funds once the 
country became ineligible for The Global Fund round 10. 
As an emergency, short-term solution, some NSPs and 
OST services are presently funded through European 
Structural Funds, but the government still refuses to lend 
its support.6 Other countries in the region may be facing 
similar circumstances within the next two to four years. 
Sustained civil society advocacy is crucial for maintaining 
and increasing concrete support for harm reduction from 
national governments across Eastern Europe.
drUg USEr invOlvEmEnT in hArm 
rEdUCTiOn rESPOnSES
Meaningful involvement31 of people who use 
drugs in service design, implementation, monitoring 
and evaluation is very scarce across Eastern Europe. In 
most countries user representation occurs largely at the 
program rather than at the organisational or policy levels.4 
Generally, representation is tokenistic or consultative, 
with former and, occasionally, active users given the 
roles of peer educators, NSP “assistants”, outreach 
workers and other “gatekeepers.”ar 4 One exception is 
Bosnia-Herzegovina, where users are represented at 
the municipal level in the country’s three largest cities, 
Sarajevo, Tuzla and Zenica, as advisers for policies 
affecting young people’s health and social inclusion.32 
Another is Bulgaria, where the only known user-run 
organisation in the country was invited to become a 
member of the National Coordinating Committee on HIV/
AIDS, opening the possibility to participate in decisions 
regarding funding for harm reduction programs.15
Barriers to the participation of people who use 
drugs at all levels of practice and policy include limited 
capacity of the few existing user-run organisations and 
networks to engage in advocacy, the criminalisation 
of drug possession for personal use and the high level 
of stigma against people who drugs.4 CSOs articulated 
the urgent need to consolidate and build the capacity 
of existing organisations of people who use drugs, raise 
public awareness and share examples of best practice 
on how to effectively and meaningfully involve users 
within service design, implementation, monitoring and 
evaluation.4 
ar Albania, Kosovo, Montenegro, Macedonia, Bulgaria, Croatia, Czech 
Republic, Slovakia. 
Civil SOCiETy And AdvOCACy
Across Eastern Europe, CSOs advocating for harm 
reduction operate mainly at the national and regional 
levels.4 Funding for advocacy activities is largely 
nonexistent, or in a few cases supported by international 
donors such as The Global fund, OSF, UN agencies 
and others.as 4 In one case, it was reported that despite 
the availability of funding for advocacy activities by 
international donors, CSOs may not have the capacity 
to engage in advocacy while they struggle to provide a 
basic level of services.33
National harm reduction networks operate in 
Romania, Macedonia, Hungary, Lithuania and the Czech 
Republic.4 In Bosnia-Herzegovina, harm reduction 
organisations are linked virtually but do not have the 
resources to mobilise into a formal national structure.32 In 
Lithuania, a new network was formed at the end of 2008 
but has yet to become active at the national level.34 The 
majority of CSOs in Eastern Europe also engage regionally 
through their participation in international networks 
such as the Eurasian Harm Reduction Network (EHRN), 
the International Drug Policy Consortium (IDPC) and 
EuroHRN. 
In all countries where information was available, 
CSOs identified the following advocacy priorities:
  Ensure adequate, predictable funding for 
harm reduction programmes from national 
governmentsat
  Reorient drug policies to reflect evidence-based 
public health and human rights-based approaches, 
including decriminalising drug use for personal 
possessionau
  Implement evidence-based harm reduction 
services, particularly NSPs, and scale up provision 
of OST, in prisons and other places of detentionav
  Scale up provision of current NSP and OST 
programmes in the community.aw
Additional advocacy priorities in the region include 
addressing stigma and discrimination against people 
who use drugs, and particularly women who use drugs;ax 
developing harm reduction training curricula for law 
enforcement and police forces;ay and increasing public 
awareness of harm reduction and drug policy issues 
as  Kosovo, Hungary, Lithuania, Romania, Slovakia. 
at  Bulgaria, Croatia, Lithuania, Macedonia, Romania, Slovakia.
au  Albania, Bosnia-Herzegovina, Macedonia, Montenegro, Romania.  
av  Bulgaria, Lithuania, Czech Republic.
aw Kosovo, Romania, Slovakia.
ax  Montenegro, Romania.
ay  Bosnia-Herzegovina.
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through mass media, social media and public debates.az 
In Bulgaria, Hungary, Romania and Slovakia additional 
priorities include advocating for evidence-based 
decision-making with regard to the recent expansion of 
the smart drugs market in Romania; protecting existing 
harm reduction services at the policy level;ba consolidating 
users’ groups and support their engagement with 
national-level policy-making;bb integrating STI testing, 
including for HIV, within NSP services;bc and advocating 
for the provision of naloxone via low-threshold harm 
reduction programmes.bd
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3.2 NORTH 
EUROPE Ireland   
United Kingdom
   
Norway
    Finland  
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  
Denmark
  
Germany
    Netherlands
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Belgium
  
Luxembourg
    
Switzerland
  
Austria
  
Needle and syringe exchange
Opioid substitution therapy
Drug consumption rooms
Prison needle exchange programme
Prison opioid substitution therapy
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Prison needle exchange programme
opioid substitution therapy
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Ireland
   
United Kingdom
   
Norway
    Finland  
Sweden
  
Denmark
  
Germany
    Netherlands
   
Belgium
  
Luxembourg
    
Switzerland
  
Austria
  
Needle and syringe exchange
Opioid substitution therapy
Drug consumption rooms
Prison needle exchange programme
Prison opioid substitution therapy
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Ireland
   
United Kingdom
   
Norway
    Finland  
Sweden
  
Denmark
  
Germany
    Netherlands
   
Belgium
  
Luxembourg
    
Switzerland
  
Austria
  
Needle and syringe exchange
Opioid substitution therapy
Drug consumption rooms
Prison needle exchange programme
opioid substitution therapy
32
table 3.2.1: Availability and coverage of harm reduction interventions in north europe 
Country Or Territory
Needle ANd SyriNge exChANge PrOgrAmme OPiOid SubSTiTuTiON TherAPy
drug 
Consumption 
rooms 
existence1 and 
Number2 
Prison Needle 
exchange 
Programme 
existence3 and 
Availability4
Prison Opioid 
Substitution 
Treatment
Availability,a 5 
initiation (i)  and 
Continuation (C)6 
Availability, 
Syringe 
Vending 
machine (S), 
And Pharmacy 
based NSP (P)7
Number of 
sites8
Syringes 
distributed 
annually 
through 
specialised 
sites per person 
injecting 
drugs b 9
Availability 
and form c 10 
Number of 
sites 11
% opioid 
users 
receiving 
OST 12 
Austria Yes (S, P) 27
Yes (M, B, 
BN, SM)
44 (42 - 
46)
No No Yes, full (I, C)
Belgium Yes (P) 34 Yes (M, B) No No Yes, full (I, C)
Denmark Yes (S, P) 135
Yes (M, 
B, H)
No No Yes, full (I, C)
Finland Yes 52
Yes (M, B, 
BN)
29 (24 – 
32)
No No Yes (C)
Germany Yes (S, P) 250
Yes (M, B, 
BN, H)
2,786-
6,626
60 (46 – 
85) 
Yes (27) Yes, rare
Yes, limited 
(I, C)
Ireland Yes 33
Yes (M, B d , 
BN e )
332
47 (41 – 
54) 
No No
Yes, extensive 
(I, C)
Luxembourg Yes (S) 4
175 (135 – 
207)
Yes (M, B, 
SM)
55 (43 – 
65) 
Yes (1)
Yes, 
extensive
Yes, full (I, C)
Netherlands Yes (P) 150
Yes (M, 
B, H)
Yes 
(approx. 
40)
No
Yes, extensive 
(I, C)
Norway Yes 22
326 (272 – 
381)
Yes (M, B) Yes (1) No
Yes, extensive 
(I f, C)
Sweden Yes 2 4 (4 – 4) Yes (M, B) No No Yes (I, C)
Switzerland Yes (P) 101
Yes (M, 
B, H)
Yes (7)
United Kingdom Yes g  (P) 1,523
Yes (M, B, 
BN, H)
46 (44 – 
47) h
No No
Yes, limited 
(Ii , C)
a. Full: substitution/maintenance treatment exists in nearly all prisons 
Extensive: exists in a majority of prisons but not in nearly all of them 
Limited: exists in more than a few prisons but not in a majority of them 
Rare: exists in just a few prisons
b. Data is from 2008 or more recent year
c.  M = methadone, B = High-dosage buprenorphine, H = Heroin assisted treatment, BN 
= Buprenorphine-naloxone combination, SM = Slow-release morphine
d. Legally available but no clients reported
e. Legally available but no clients reported
f.  Initiation of OST has to be carried out by an external regional maintenance treatment 
provider
g.  Except in Northern Ireland where there are no fixed specialist NSP sites
h. Data from England only 
i.  Except in Northern Ireland
1. European Monitoring Centre on Drugs and Drug Addiction (2010) Drug 
consumption facilities in Europe and beyond, in Harm Reduction Monograph: Harm 
reduction: evidence, impacts and challenges.
2. European Monitoring Centre on Drugs and Drug Addiction (2009) NR 2009
3. European Monitoring Centre on Drugs and Drug Addiction (2010) Statistical Bulletin: 
Table HSR4. Year of introduction of needle and syringe programmes (NSPs) and 
types of programmes available in 2008 .
4. European Monitoring Centre on Drugs and Drug Addiction (2009) Statistical Bulletin: 
Table HSR-7. Availability and level of provision of selected health responses to 
prisoners in 26 EU countries, Norway and Turkey (expert ratings).
5. European Monitoring Centre on Drugs and Drug Addiction (2009) Statistical 
Bulletin: Figure HSR-2. Provision of substitution/maintenance treatment (OST) in the 
community and availability of OST programmes in the prison.
6. European Monitoring Centre on Drugs and Drug Addiction (2010) Statistical Bulletin: 
Table HSR9. Opioid substitution treatment in prison in EU 27, Croatia, Turkey and 
Norway.
7. European Monitoring Centre on Drugs and Drug Addiction (2010) Statistical Bulletin: 
Table HSR4. Year of introduction of needle and syringe programmes (NSPs) and 
types of programmes available in 2008 .
8. Mathers B et al (2010) HIV prevention, treatment and care for people who inject 
drugs: A systematic review of global, regional and country level coverage. Lancet 
375 (9719):1014-28.
9. European Monitoring Centre on Drugs and Drug Addiction (2010) Statistical Bulletin: 
Figure HSR-3. Syringes distributed through specialised programmes per estimated 
IDU in 2008 or more recent year.
10. European Monitoring Centre on Drugs and Drug Addiction (2010) Statistical Bulletin: 
Table HSR1. Table HSR-1. Year of introduction of methadone maintenance treatment 
(MMT), high-dosage buprenorphine treatment (HDBT), buprenorphine/naloxone 
combination, heroin-assisted treatment and slow-release morphine 
11. Mathers B et al (2010) HIV prevention, treatment and care for people who inject 
drugs: A systematic review of global, regional and country level coverage. Lancet 
375 (9719):1014-28.
12. European Monitoring Centre on Drugs and Drug Addiction (2010) Statistical Bulletin: 
Figure HSR-1. Opioid substitution treatment clients as a percentage of the estimated 
number of problem opioid users, 2008 or most recent year available.
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harm reduction in north europe
the authors would like to acknowledge the contributions of the 
following organisations in providing information for their specific 
countries:a
 Verein wiener sozialprojekte (Austria); Free Clinic (Belgium); 
gadjuristen (Denmark); A-Clinic Foundation (Finland); akzept 
(germany); irish needle exchange Forum, Citywide Drugs Project 
(ireland); Correlation network (netherlands); randi ervik, Assistant 
Professor, Diakonhjemmet university College (norway); swedish 
Drug users union (sweden); infodrog (switzerland), Contact netz 
(switzerland), groupement romand D’etudes des Addictions 
(switzerland); the uk harm reduction Alliance (united kingdom)
Harm reduction has been a longstanding public health approach used in practice and policy in most North European countries. Key interventions 
such as NSPs and OST form an integral component of drug 
services across the region. Nearly half of the countries in 
the region operate DCRs and provide HAT. 
However, the accessibility and scope of harm 
reduction services remains limited in several settings and 
among particular subgroups of people who use drugs. 
There is a substantial need to integrate HIV, viral hepatitis 
and tuberculosis prevention and treatment, and reduce 
restrictions on their accessibility. Despite the scale up of 
harm reduction interventions in prisons over the last two 
decades, barriers to access remain, particularly around 
treatment continuity pre- and post-release from prison. 
Availability of prison-based NSPs is a major gap, with 
provision limited to two countries in the region.  Other 
harm reduction initiatives, such as naloxone distribution 
and safer nightlife initiatives, remain to be adequately 
scaled up.
In recent years, several countries have experienced 
political changes that have threatened support for harm 
reduction initiatives. Effective advocacy is urgently 
required to scale up coverage to adequate levels, prevent 
the ‘roll-back’ of achievements already gained and to 
retain harm reduction on national policy agendas. 
Direct involvement of people who use drugs in 
service planning, implementation, monitoring and 
evaluation remains limited. There is a need for greater 
recognition and empowerment of organisations of 
people who use drugs as partners at the organisational 
and policy-making levels.
a Questionnaire response from Luxembourg not available at the time of 
writing.
Civil sOCiETy ORgaNisaTiONs HavE idENTifiEd 
sEvERal advOCaCy PRiORiTiEs fOR THis 
REgiON. THEsE iNClUdE:
  Provide and increase access to DCRs, NSPs and 
OST (including HAT) 
  Improve coverage and integration of HIV, viral 
hepatitis and TB prevention and treatment 
services
  Provide basic housing and social support for 
homeless people who use drugs
  Develop national and pan-European drug user 
and civil society networks
  Advocate for drug policy change and in 
particular, decriminalisation of drug use.
 
NEEdlE aNd syRiNgE ExCHaNgE 
PROgRammEs (NsPs)
NSP sites operate in all states in the region, but 
coverage varies considerably (see table 3.2.1).1 Several 
NSP service delivery modelsb are implemented across 
the region to varying degrees. For instance, Sweden and 
Norway rely on one type of outlet,2 whereas in Austria, 
Denmark, Luxembourg and Germany, needle and syringe 
distribution through fixed outlets is supplemented by 
vending machine distribution.3 Mobile NSP sites operate 
in nearly half of the countries in this region.c 4 The 
availability of a variety of service provision models may 
increase NSP access for some groups of who inject drugs 
that may not access fixed sites regularly.5 For instance, 
mobile van sites and public vending machines have been 
shown to attract younger people who inject drugs and 
those with higher risk profiles more effectively than other 
NSP delivery models.5
A majority of countries have moderate to high 
coverage of sterile injecting equipment distribution.d 
6 Among these is Norway, the country with the highest 
b Service delivery models include fixed specialist sites, those situated 
within drug services, pharmacy-based NSPs and mobile distribution 
(including peer outreach).
c Austria, Finland, Ireland, Netherlands, and UK.
d Targets for syringes distributed per person injecting drugs per year as 
defined by WHO, UNODC and UNAIDS (2009) guidelines are low (£100), 
medium (>100–£ 200) and high (>200). These countries include Austria 
(176), Finland (166), Ireland (164), Luxembourg (144), Netherlands (127), 
Norway (434), and the UK (188).
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reported coverage in North Europe and globally.e 8 
However, many CSOs report inadequate coverage 
outside of main cities and in rural areas.f 7 Irish NSP 
service provision outside Dublin, for instance, is limited 
or nonexistent,22 and in Belgium and Denmark, coverage 
remains low.8 
In some countries, limited hours of operation and 
age restrictions are reported to impede access to NSPs.g 
7 In Finland, Ireland and Sweden, operational barriers 
are compounded by psychosocial deterrents to service 
access, including fear of police surveillanceh and stigma 
toward people who use drugs.i 7
In countries where political support for harm 
reduction is present, CSOs report that a lack of financial 
supportj and insecure fundingk remain impediments to 
NSP scale up.7  
Non-opioid injecting, such as the use of anabolic 
steroids and performance-enhancing drugs (PED), has 
been reported in Belgium and the UK.7 9 10 But a shortage 
of data on the prevalence of steroid and PED injecting, its 
low priority within national drug budgets and inadequate 
national NSP monitoring systems, have prevented the 
development of targeted strategies to address this user 
group’s needs (for more information see box below).l 
A recent increase in non-injecting routes of 
administration (NIROA) and a decrease in drug 
injecting have been documented in some countries.7 11 
e  Mathers et al. (2010) reports that in Norway 434 syringes are distributed 
per person injecting drugs per year.
f Austria, Belgium, Finland, Germany, Ireland, Switzerland and Sweden.
g  Belgium, Denmark and the UK.
h  Finland.
i  Finland, Ireland and Sweden.
j  Norway, Ireland.
k  Germany, Switzerland, UK.
l  Evidence suggests that this group may use NSPs differently than other 
people who inject drugs. For instance, research has shown that 
people who inject steroids make fewer visits per year and collect large 
numbers of syringes in a single visit (McVeigh et al. 2003).
Interventions to facilitate transitions away from injecting 
(route transition interventions or RTIs),12 to reduce and 
prevent injecting drug use and to promote safer non-
injecting drug use are available in some countries 
as additions to existing harm reduction services. For 
instance, CSOs report that safer crack smoking kitsm are 
widely distributed in the Netherlands, but numbers of 
people reached are unknown,40 and distribution outside 
the Netherlands remains very limited.n 7 Recent civil 
society efforts to amend existing laws prohibiting the 
distribution of crack smoking kits, aluminum foil and 
other RTIs in the UK have resulted in a recommendation 
by the Independent Advisory Council on the Misuse 
of Drugs to include aluminium foil to the current list of 
permitted items.13 
OPiOid sUbsTiTUTiON THERaPy (OsT)
Methadone maintenance therapy (MMT) and 
buprenorphine maintenance therapy (BMT) are 
implemented in all North European countries (see 
table 3.2.1).o Additional OST options, such as HAT, 
buprenorphine plus naloxone combination and slow-
release morphine, are available across the region, except 
in Belgium, Norway and Sweden. Almost half of the 
countries in the region provide HAT, with pilot projects 
underway in Belgium and Luxembourg.14 
m  Safer crack kits typically include a heat-resistant glass stem/pipe, a 
rubber mouthpiece, brass screens and occasionally alcohol swabs, 
ascorbic acid and lip balm.
n  Safer crack use kits are provided through some facilities in Denmark, 
Germany and through unofficial channels in Ireland and the UK.
o  Buprenorphine provision is legal in Ireland but there are no clients 
utilising this service.
The use of anabolic steroids or performance enhancing drugs 
(PEDs) is on the rise in Europe, and particularly in the UK.  Although 
systematic data on this issue is scarce, figures for England and 
Wales are provided by the British Crime Survey (BCS). The BCS 
estimates that in the 16-59 year old age group around 226,000 
people admitted to ever having used anabolic steroids, with 
50,000 having used in the past year, and 19,000 in the past month.a 
More than 70% of users in the UK inject PEDs.b Reports suggest 
that steroid injecting is on the rise predominantly amongst 
young men. A study conducted between 1999 and 2006 of 
agency-based syringe-exchange programmes showed a six foldc 
increase in the number of steroid injecting clients accessing the 
service.  An examination of NSPs between 1991 and 2006 showed 
a 2000% increase in steroid injectors attending this service.d  
A range of adverse effects hav  been associated with PEDs, 
ranging from physical and psychological harms to death. Steroid 
a   Advisory Council on the Misuse of Drugs (2010) Consideration of the 
Anabolic Steroids. ACMD: London.
b   Evans-Brown M, McVeigh J. An introduction to anabolic steroids. 
sportEX medicine 2008:38(oct):20-26
c   McVeugh J, , Beyron C, Bellis MA. New challenges for agency based 
syringe exchange schemes: analysis of 11 years of data (1991 – 2001) 
in Merseyside and Cheshire, UK. International Journal of Drug Policy 
2003;14:353-357
d   McVeigh J, Chandler M, Bynon C, Evans-Brown MJ, Bellis MA. The 
injectors that harm reduction forgot. 18th International Conference 
on Drug Related Harm 2007
injecting is associated with multiple health harms including 
damage to the injection site, abscesses and blood borne viruses 
such as HIV and Hepatitis C. 
Steroid use may be driven by a complex cocktail of structural 
and social factors including media, peer influence, occupation 
and body image dissatisfactione. This is an emerging issue for the 
harm reduction community, and more research is needed to fully 
understand the needs of this diverse group.
Key harm reduction points for practitioners working with 
individuals that use PEDs (adapted from ‘An introduction to 
anabolic steroids’)f:
  Use the smallest dose of steroids and do not adopt 
other users’ regimes
  Limit the length of On cycles
  Be aware of counterfeit drugs
  Always use sterile injecting equipment
  Know how to inject safely. Do not share equip ent
  Spend adequate time on training nutrition and sleep
  Know the dangers of recreational drug use
  Be aware of side effects. At the first sign of them, 
disc nti ue use a d seek medical advice.
e   Evans-Brown M, McVeigh J. An introduction to anabolic steroids. 
sportEX medicine 2008:38(oct):20-26
f   Evans-Brown M, McVeigh J. An introduction to anabolic steroids. 
sportEX medicine 2008:38(oct):20-26
PERfORmaNCE ENHaNCiNg dRUgs (PEds) 
maria Phelan
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The nature of OST provision varies from distribution 
through privately and publicly funded clinics to 
pharmacy dispensing programmes.15 In some countries, 
this includes access through general practitioners (GPs),14 
although levels of regulation governing OST prescription 
by GPs vary considerably across the region.p For instance, 
in Norway GPs are not legally entitled to assess a patient’s 
need for OST and provide treatment, but they can assume 
responsibility for a patient from a specialised OST centre.15 
In Finland and Ireland, GPs are authorised to prescribe 
OST, but few are reported to do so.7 
The variety in service provision alternatives and a 
lack of national standardised indicators for monitoring 
OST implementation make it challenging to estimate the 
number of OST outlets operating in each country.16 17
In some countries, OST access and provision remain 
inadequate, especially outside major cities, due to rising 
patient demand for treatment and a shrinking supply of 
GPs who are accredited or willing to provide it.7 In Austria 
and Germany, strict regulatory frameworks governing 
OST prescription, specialised OST licensing and enforced 
criminal sanctions have been reported to discourage GPs 
from undertaking OST accreditation, and from actively 
prescribing it once accredited.7 18 
In some countries, service access is limited by long 
waiting lists for entryq and rigid bureaucratic procedures 
governing patient eligibility, assessment, start-up and 
supply.r 7 For instance, waiting times of 13 months for OST 
eligibility assessment have been reported in Ireland.7 In 
Norway, criteria for accessing OST include a minimum 
age of 25 years, with new guidelines being developed 
at the time of writing.19 Even in countries where no age 
restriction for OST access exists, there have been reports 
of young users being denied access to OST or being 
referred to abstinence-based services instead.s 7 In the 
UK, supervised consumption requirements and time 
limitations in terms of treatment duration18 may pose 
additional barriers to treatment effectiveness.7 
A decentralised approach to treatment provision 
in a number of countries means that political support for 
OST scale up must be sought at multiple levels. Increasing 
funding cuts, stigma associated with both accessing and 
prescribing OST, and a lack of evidence-based standards 
for OST provision and quality of care have been reported 
to further challenge OST access and scale-up.7
p  Austria, Belgium, Finland, Germany, Ireland, UK.
q  Austria, Finland, Ireland, Sweden, Norway.
r  Denmark, Finland, Norway, Sweden, UK.
s  Belgium, Netherlands.
dRUg CONsUmPTiON ROOms (dCRs)
The majority of DCRs in the world operate in five 
North European countries (see table 3.2.1).20 Adequate 
DCR coverage has increased clients’ access to health, 
treatment and social services, and reduced public drug 
use, without incurring any harms.20 DCRs also enable 
rapid intervention during an overdose, thus reducing 
the occurrence of fatal overdoses and the health risks 
associated with non-fatal overdoses.14 21
In countries where DCRs operate, several factors are 
reported to limit access to this intervention. In Germany, 
for instance, OST recipients cannot legally utilise DCRs;22  in 
Switzerland, access is limited to residents of the province 
in which the facility is located.25 The only DCR in Norway 
has limited opening hours and only allows the injection 
of heroin on its premises,14 and in the Netherlands, the 
acceptance criteria are strict.t 42
Legal and political barriers prevent the piloting and 
implementation of DCRs in other countries in the region.7 
23   
Hiv, viRal HEPaTiTis aNd 
TUbERCUlOsis (Tb) sERviCEs
HIV testing and treatment services
Despite the free availability of HIV testing and 
treatment in many states in the region, several factors 
impede uptake of these services. In Ireland, the 
requirement to make an appointment for HIV counselling 
and testing (VCT) and to be enrolled in MTT as a condition 
for ART access have been reported as obstacles  for some 
people who use drugs.24 23 
Access to ART for people who inject drugs that 
are living with HIV varies among countries, from high 
estimated coverageu in places such as Finland, Germany 
and the Netherlands, to medium coverage in Norway, 
the UK, Luxembourg and Austria.8 In Switzerland, ART is 
only available to health insurance holders and enrolment 
in MMT is a prerequisite for ART access.25 Across the 
region, CSOs suggest that fear of stigmatisationv, fear 
of legal repercussions,w lack of motivationx and distrust 
t   Criteria includes an age restriction, evidence of long-term, problematic 
drug use, homelessness, police background check, and submission of 
personal identification to the police.
u  Indicative coverage targets for ART are subject to debate. Since the 
highest coverage achieved in high-income countries is 75–80%, the 
target setting guidelines consider coverage of over 75% high-level 
coverage. The targets for effective response to viral hepatitis and 
tuberculosis are likely to be higher (WHO, UNODC, UNAIDS 2009). 
v  Finland, Ireland.
w   Ireland.
x   Sweden.
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of government institutionsy may restrict service access.7 
While service integration between harm reduction and 
HIV services is not the norm across the region, some 
providers offer routine HIV testing upon admittance to 
OST programmes.7 
Viral hepatitis testing and treatment 
services
Hepatitis B vaccination programmes targeting 
specific high-risk groups, including people who inject 
drugs, operate in most countries.z 26 However, CSOs 
reported that access to HIV, hepatitis and TB testing and 
specialised services is often less available outside of large 
cities.7 
There are significant barriers to the diagnosis and 
treatment of viral hepatitis among people who inject 
drugs, particularly in the context of co-infection with HIV. 
In Austria, Finland and Ireland, CSOs report that the stigma 
attached to hepatitis C (HCV) may influence access to 
treatment.7 Limited integration and weak referral systems 
among drug services, particularly outside of main cities, 
have been cited as impediments to the diagnosis and 
management of HCV.aa 7 
The cost of HCV treatment remains prohibitive 
for subgroups of people who use drugs in a number of 
countries. For example, in Germany, the cost is not covered 
by health insurance.7 Similar policies in Switzerland pose 
considerable financial obstacles for the uninsured.7 In 
Finland, HCV treatment is not presently offered to people 
who are actively using drugs.7 Additional barriers cited by 
CSOs include limited awareness regarding the availability 
of HBV and HCV testing and treatment, inadequate 
knowledge of the harms associated with HBV and HCV/
HIV co-infection among health professionals, limited HCV 
testing options and lack of national data collection on 
viral hepatitis.ab 7
 
Tuberculosis testing and treatment services
The extent of coverage for viral hepatitis and TB 
services is largely unknown.15 16 Barriers to TB detection 
and management, especially TB/HIV co-infection include 
limited coordination among drug agencies, differences in 
practices within countries, lack of awareness around the 
prevalence and harms of TB and low prioritisation of this 
issue in terms of service capacity.7 An increase in cases of 
y   Austria. 
z   Belgium (French-speaking community), Denmark, Germany, 
Netherlands, Austria, Finland, Sweden, United Kingdom and Norway.
aa Austria, Denmark, Finland and the UK.
ab For instance, CSOs in Ireland cite the lack of availability of dry spot 
blood testing.
TB among migrants who use drugs has been reported 
in Ireland, Sweden and Switzerland but data on figures 
among this population are unknown.7
The presence of HIV infection and other factors 
including incarceration, homelessness and poverty may 
increase vulnerability to TB infection among people who 
inject drugs.27 Increased availability, access and advocacy 
for housing support, vocational counselling and social 
assistance are particularly relevant in the context of 
HIV, viral hepatitis and TB infection. Social reintegration 
initiatives that are not reliant upon abstinence or 
treatment have been recognised as an “essential 
component of comprehensive drug strategies.”14
HaRm REdUCTiON iN PRisONs
Three out of 10 countries worldwide that have 
introduced NSPs in prisons are located in this region (see 
table 3.2.1).ac 15 Service models vary and include injecting 
equipment exchanges and automated syringe vending 
machines.27 All countries offer OST to prisoners, but 
coverage varies widely within and among countries.28 29 
Switzerland is the only country globally to provide HAT 
to prisoners in two facilities.30 Existing harm reduction 
programmes have not been scaled up nationally 
across prison systems, leaving gaps between need and 
provision,7 27 and the implementation of harm reduction 
services is often dependent upon the policies of 
individual provinces and prison directors, which renders 
service provision inconsistent.7 31
Although the scope of OST has extended 
considerably across Europe in the past two decades,23 
24 CSOs in a majority of countries report that in many 
prisons the focus remains on drug control rather than 
evidence-based harm reduction interventions.7 
OST access and continuity in prisons continues to 
lag behind the standards of OST in the community.23 32 
Constraints to substitution treatment access for specific 
target groups persist within some countries. For example, 
in Bavaria, Germany, only opioid-dependent prisoners 
living with HIV or those who are at an advanced stage of 
pregnancy are offered OST.ad  25 Sweden, in comparison, 
has four detention centres that provide OST with strict 
access criteria.ae 33
ac Germany, Luxembourg, Switzerland.
ad Statistical analysis has shown that treatment is often only marginally 
better in other German states: the coverage ratio is only about 3% 
compared to 30–50% OST coverage in the community (Stöver H. et al. 
2008).
ae The programme accepts only 14 individuals who must be able to 
show evidence of a steady address or apartment, as well as active 
employment or student status.
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Across the region, continuity of treatment and care 
is interrupted or changed as a result of detention, during 
detention or when making the transition to living in the 
community upon release from prison. For instance, in 
Finland and Sweden, OST is continued in prison only if 
the prisoner was already undergoing treatment prior to 
arrest.7 A study in Germany found that 70% of opioid-
dependent prisoners had to stop treatment when they 
entered prison.34 Lack of continuity of care upon initiation 
and release affects the quality and benefits of OST, 
denying opioid-dependent prisoners the opportunity to 
stabilise their lives and improve their health outcomes.35
OvERdOsE REsPONsEs
Across the North Europe region, overdose 
prevention responses including the provision of 
overdose information material to people who use drugs, 
individual overdose risk assessment, overdose response 
trainingaf and risk education on drug-related deaths 
are implemented to varying degrees.36 The provision 
and reach of overdose prevention responses, excluding 
provision of naloxone, varies from extensive in Ireland, 
Finland, Germany and the United Kingdom to limited 
or rare in Belgium (particularly the French community), 
Sweden and Norway.36 
Naloxone availability is limited in most countries 
in the region. Peer distribution is practised in Denmark, 
but intervention coverage is limited to Copenhagen.7 In 
the UK no formal peer distribution network exists.7 CSOs 
report a number of barriers to scaling up peer distribution 
of naloxone in the UK, including prescription laws limiting 
the transportability of naloxone, police attendance at 
emergency calls for drug overdose and fear of arrest.7 
In Finland, Ireland and the Netherlands, naloxone 
is available only to medical emergency response staff,7 
and in Germany a limited number of drug treatment 
institutions offer naloxone, but the extent of coverage is 
not known.7 Naloxone is not available in Austria, Belgium 
and Sweden.7 
There are a number of obstacles to implementation 
and scale-up of overdose prevention programmes, 
including peer distribution of naloxone. These include 
a lack of reliable, comparable and baseline data on 
overdose and legal barriers, particularly around naloxone 
administration and transportability by non-medical staff.7 
As a result, interventions are often “sporadic and limited.”14 
A number of pilot projects are presently underway,37 
af  The EMCDDA (2010) defines overdose response training as: “one-to-
one or group education sessions on risks, prevention of risks and on 
management of overdoses, which should include information on risk 
situations and risk behaviour, how to recognise overdoses, and how to 
respond adequately (at least the recovery position).”
UsER-fRiENdly sERviCEs: 
bETwEEN gOOd PRaCTiCE aNd 
a RUbbER HammER 
John-Peter Kools
“In many countries users are no longer treated as criminals, 
but as patients or clients. Is that an improvement: criminal or 
patient? That’s like being hit by an either an iron hammer or a 
rubber one. A rubber one is preferable, but it’s still a hammer.” 
– a drug user activist 
User-friendliness (UF) is commonly recognised as a key 
principle of good quality service delivery. Although many 
users of harm reduction services will immediately identify 
whether a service is user-friendly, it is challenging to 
articulate what that constitutes. There is no standardized 
checklist of components, but some key elements related 
to technical service-delivery and attitude can be identified:
  accessibility  (Do the location/opening times match 
clients’ schedules, giving them as many opportunities 
as possible to access the service?)
  appropriateness of services delivery (Does the 
service provide what clients really need?)
  satisfaction (Are clients asked to reflect on the quality 
of services?)
  ability to influence service-delivery (Is there 
a client council or some other formal/informal 
consultation of clients, and is it implemented in 
practice?)
  Peer involvement (Is there meaningful peer 
involvement in the development, management and /or 
delivery of services?)
  Non-judgmental attitude of staff (Are clients 
treated with dignity and respect of staff?)
  safety (Does the service provide physical safety from 
violence, intimidation, interference from others –
including police?)
  Privacy (Are service users’ details being treated 
confidentially? Are client data well protected?)
  Proportionality (Are the agency regulations and 
requirements proportional to the direct health and 
social benefits of the service?)
  Ownership (Do people feel that that the service is 
primarily for them, not for the sake of the organisation 
or, for instance, to reduce public nuisance?)
User-friendly qualities are essential to service effectiveness. 
If people appreciate a service, they are more likely to use 
it, which benefits everyone: user, provider and the wider 
community.
38
including a large-scale randomised controlled trial 
of naloxone distribution to prisoners upon release in 
England.38 Across the region, it is important for people 
who use drugs and CSOs to lobby for peer distribution of 
naloxone and its integration within mainstream drug and 
harm reduction services.
HaRm REdUCTiON fOR RECREaTiONal 
dRUg UsE 
Safer nightlife initiatives, including pill testing, 
outreach, counselling in recreational settings, and 
information and education campaigns, are implemented 
in Austria, Germany, Switzerland, Denmark, Norway 
and the Netherlands to varying degrees.7 Pill testing is 
omitted from Switzerland’s federal law on drugs, and 
the authority to allow drug testing rests with each of 
the 26 Swiss cantons.39 40 Several cantons in the German-
speaking parts of the country, including Zurich, have 
authorised this intervention.38
With the exception of initiatives in Austria and the 
Netherlands, which are partly funded and supported by 
the government, programmes in the majority of countries 
are self-funded, privately-funded or run by volunteers.7 
In the Netherlands, on-site pill testing in party settings 
has been prohibited since January 2002, but it remains 
accessible through the Drugs Information and Monitoring 
System, with self-tests also available in smart-shops and 
over the internet.41 7 In Denmark, the main source of 
harm reduction information for partygoers is a peer-run 
website.ag 7 
In the majority of states, significant challenges 
to coverage and quality of safer nightlife initiatives 
remain. These include a lack of coordination among 
existing initiatives, lack of comparable and complete 
data on effectiveness and coverage, and prioritisation of 
“problem drug use” rather than recreational drug use in 
programme funding, research and policy.7 
Documented growth of international travel 
associated with nightlife suggests that scale-up of 
evidence-based interventions promoting health and 
safety may be required internationally.42
Safer nightlife initiatives such as distribution of 
free water, availability of immediate emergency care 
and outreach with party-goers, are provided by several 
organisations in Europe. In 2010, the Netherlands-based 
Trimbos Instituut launched a how-to handbook on 
ag  http://www.psychedelia.dk.
Drug consumption rooms (DCRs) are professionally supervised 
healthcare facilities where problem drug users can consume 
their drugs under safer and more hygienic conditions. Europe 
leads globally on DCR coverage, with six European countries 
(Germany, Luxemburg, Norway, Spain, Switzerland, and The 
Netherlands) having established DCRs in response to open 
drug scenes and public drug use. DCRs try to encourage safer 
drug use, improve the health status of drug users and reduce 
public nuisance.  While DCRs contribute to the prevention 
of the spread of infectious diseases such HIV and HCV, they 
also reduce exposure to overdose.  While most DCRs target 
injecting drug users, in The Netherlands, Germany, Spain and 
Switzerland, separate facilities are also offered to people who 
smoke cocaine (crack) and/or heroin. 
‘Specialised’ or stand-alone DCRs only offer a safe injecting 
space, whereas ‘integrated’ consumption rooms are also offer 
medical, social and treatment services to substance users. 
DCRs have increased access to services for ‘hard-to-reach’ drug 
users in particular and contributed to new forms of services, 
such as  hepatitis testing and treatment for people who inject 
drugs in Amsterdam or Chill Out rooms (“Tagesruheräume”) 
for cocaine users in Frankfurt and Bremen. Where coverage, 
capacity and opening hours are sufficient to cover local needs, 
DCRs could help reduce overdose deaths. 
Public drug use is associated with feelings of insecurity 
amongst community members where such facilities are 
located and the general public. DCRs can reduce the level 
of public drug use, but this depends on their accessibility, 
opening hours and capacity. 
Evidence recently reviewed by the EMCDDA indicates that, in 
settings where public drug consumption poses serious public 
health and social order concerns, DCRs may have specific 
benefits for individual and public health and social order. 
They have become a primary ‘point of access’ to services for 
those most at risk and who are out of reach of more traditional 
service providers. 
Their impact is most tangible when part of a pragmatic, 
flexible and comprehensive approach to problem drug use 
addressing the associated individual and social harms at 
community level. Such an approach may include abstinence 
and various forms of drug substitution treatment, social 
services, such as supported housing, day spending facilities, 
reintegration and labour training, as well as medical and 
psychiatric treatment. 
Sources:
Hedrich, D., Kerr, T. and Dubois-Arber, F. Drug consumption facilities 
in Europe and beyond. In: Rhodes, T. and Hedrich, D. (2010) Harm 
reduction: evidence, impacts and challenges. EMCDDA Monograph 
10. Luxembourg: Publications Office of the European Union. 
Hedrich, D. (2004), European report on drug consumption rooms, 
EMCDDA, Lisbon.
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working effectively with relevant stakeholders to create 
safer nightlife settings.ah 43 
POliCy sUPPORT fOR HaRm 
REdUCTiON
All countries in the region explicitly mention harm 
reduction in their national drug policy documents (see 
table 3.2.1).44 In Austria, harm reduction is also supported 
sub-nationally, with a mandate to implement NSP and 
OST in each province, whereas Sweden’s national drug 
action plan emphasise abstinence-based approaches 
and zero-tolerance for drugs despite providing funding 
for CSOs that lobby for harm reduction.ai 7 
Despite policy support at national levels, 
implementation of harm reduction initiatives within 
many countries rests with sub-national health authorities. 
As a result levels of coverage vary within countries and 
increased pressure is placed on CSOs and user groups 
to lobby at the local level. For example, despite the 
existence of a national law allowing NSPs to operate in 
Sweden,aj NSP implementation relies on municipality and 
city council approval, limiting coverage to the south of 
Sweden.7 
The current period of economic austerity has had a 
negative impact on harm reduction.7 In the UK, changes 
in government and substantial public spending cuts 
have destabilised financial and policy support for harm 
reduction.  Following a relatively predictable stream 
of support for harm reduction since the 1980s, the 
UK government’s 2010 drug strategy mentions harm 
reduction briefly, placing a disproportionate emphasis on 
recovery through abstinence-based approaches.45 
In some countries where harm reduction has 
traditionally been an integral part of national drug 
strategies,ak  there is growing concern around the 
development of social control and surveillance 
components alongside integrated harm reduction 
services. 46 The scale up of DCRs in Amsterdam provides 
a telling example: in 1998 the police in Amsterdam began 
to advocate for the creation of DCRs on a par with harm 
reduction activists and health services. While this resulted 
in close cooperation between the police forces and DCRs, 
a system developed where the police often referred drug 
ah   The accompanying website, the Healthy Nightlife Toolbox (http://www.
hnt-info.eu/), also provides a database with relevant literature and 
documentation of existing interventions.
ai  Preliminary results of a 2010 government evaluation in Sweden have 
suggested the need for implementation of a wider harm reduction 
definition that extends beyond NSP and OST provision to include HAT, 
and to distinguish between problematic and recreational drug use.
aj  Swedish law on NSPs is presently under review. 
ak Germany, Netherlands, Switzerland and to some extent, the United 
Kingdom.
users to the DCRs, but also became controlling and had 
full access to visitor lists.47
A second, related phenomenon is the visible shift 
from harm reduction services as a human rights-based set 
of interventions toward a highly integrated, medicalised 
and streamlined approach more appropriately deemed 
‘harm management.’ 48 For instance, the three largest 
cities in the Netherlandsal  implement a comprehensive 
service provision system which includes harm reduction 
programmes alongside social benefits, housing, medical 
care and re-integration into the labour market.47 Some 
have argued, however, that the aims of effectiveness 
and efficiency have trumped the human rights and 
ethical aspects of service provision, and have turned the 
individual into ‘a mouse in a labyrinth’: an object rather 
than subject of interventions.43 
dRUg UsER iNvOlvEmENT iN HaRm 
REdUCTiON REsPONsEs
Widespread, meaningful involvement of people 
who use drugs at the multiple levels that fulfill the greater 
involvement principle is rare across the region.am 49  In 
the Netherlands, where user-led groups pioneered harm 
reduction initiatives globally in the 1970s, CSOs report 
that most user-led initiatives are presently dormant or no 
longer directly involved in service development.50 
Despite CSO reports of involvement in negotiations 
around user access to servicesan, peer work as part of harm 
reduction service provisionao and legal consultations 
related to drug useap, participation is limited to a few 
organisations in main cities.7 In the majority of countries, 
the involvement of people who use drugs in service 
design, planning and evaluation is restricted to tokenistic 
consultations, often with well-known user advocates.7
A number of CSOs highlighted the need for 
greater direct involvement in all phases of service 
planning and implementation, as well as increased user 
group involvement in drug policy matters.7 The explicit 
recognition and empowerment of people who use drugs 
al  Amsterdam, Rotterdam and Utrecht.
am   A typology of drug user participation in harm reduction responses 
has been previously represented as a “pyramid of involvement” which 
describes a range of increasingly-involved roles for people who 
use drugs, from passive target audiences, to tokenistic speakers or 
representatives, and finally, to equal participants in decision-making 
bodies. Three forms of greater user involvement have been described: 
individual-level involvement in the work of CSOs; organisational-level 
involvement in the form of participation in consultations, decision-
making and policy-making bodies; and drug user organising, which 
refers to more autonomous groups of people who use drugs who work 
toward self-determined agendas affecting their interests. 
an  Germany
ao  Finland
ap  Denmark
40
and their organisations as valuable partners at the service 
provision, organisational and policy-making levels 
was cited as an area for improvement.7 This includes 
support through funding and capacity building and the 
development of organisational systems.40
Civil sOCiETy aNd advOCaCy
Civil society organisations advocating for harm 
reduction have an established presence at multiple levels 
across the region.7 
Funding for advocacy initiatives is provided by 
national and local governments through Ministries of 
Health and through local health and welfare services 
in half of the countries in North Europe.aq 7 The 
Netherlands and the UK are the only countries that 
finance harm reduction advocacy both domestically 
and internationally.7 Other reported funding sources 
for advocacy activities across the region include the 
pharmaceutical industry,ar European regional networks 
and private organisations. CSOs in Denmark, Belgium, 
and the UK report that funding specifically allocated to 
advocacy is lacking.7
National harm reduction networks are reported to 
be active in Germany, the United Kingdom and Ireland.7 
In the Netherlands, the creation of a national network is 
presently underway.41 Across the region, CSOs expressed 
the need to strengthen coordination and partnerships 
with organisations across Europe.7 
CSOs identified several key advocacy issues across 
the region. In nearly half of the countries, advocacy 
priorities included:
  Provide and increase access to DCRs, NSPs and OST 
(including HAT) as 
  Improve coverage and integration of HIV, viral 
hepatitis and TB prevention and treatment 
servicesat 
  Provide basic housing and social support for 
homeless people who use drugsau 
  Develop national and pan-European drug user and 
civil society networksav 7 
  Advocate for drug policy change and in particular, 
decriminalisation of drug use.aw
aq  Austria, Finland, Germany, Netherlands, Sweden, Switzerland.
ar  Germany.
as  Austria, Belgium, Denmark, Finland, Germany, Ireland, 
Sweden. 
at  Austria, Germany, Switzerland.
au  Sweden, Germany, Denmark, Belgium.
av Denmark, Germany, Finland
aw Sweden, Germany, Denmark, Belgium
Additional reported advocacy priorities in the region 
included upholding harm reduction on national policy 
agendas,ax developing user and civil society networks,ay 
improving access to and integration of testing and 
treatment for HIV and viral hepatitis,az and implementing 
heroin-assisted therapy.ba  In countries where problematic 
drug use has been reported among foreign nationals,bb 
eliminating limits to service access based on proof of 
insurance or citizenship was also identified as a priority.7 
A small number of countries prioritised engaging the 
public in the harm reduction debate,bc promoting safer 
nightlife initiatives,bd improving access to OST in prisonsbe 
and increasing the availability of naloxone for overdose 
management.bf 7
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EuRoPE
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   
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   
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    Finland  
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  
Denmark
  
Germany
    Netherlands
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Belgium
  
Luxembourg
    
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  
Austria
  
Needle and syringe exchange
Opioid substitution therapy
Drug consumption rooms
Prison needle exchange programme
Prison opioid substitution therapy
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FranCe
GreeCe
Italy
Malta
portuGal
spaIn
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   
France
   
Greece
    
Italy
   
Malta
   
Portugal
   
Spain
    
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table 3.3.1: availability and coverage of harm reduction interventions in south europe 
Country or Territory
Needle ANd SyriNge exChANge ProgrAmme oPioid SubSTiTuTioN TherAPy
drug 
Consumption 
rooms 
existence1 and 
Number2 
Prison Needle 
exchange 
Programme 
existence3 and 
Availability4
Prison opioid 
Substitution 
Treatment
Availability,a 5 
initiation (i)  and 
Continuation (C)6 
Availability, 
Syringe 
Vending 
machine (S), 
And Pharmacy 
based NSP (P)7
Number of 
sites8
Syringes 
distributed 
annually 
through 
specialised 
sites per person 
injecting 
drugs b 9
Availability 
and form c 10 
Number of 
sites 11
% opioid 
users 
receiving 
oST 12 
Cyprus Yes 1 0 (0 - 0) Yes (B, BN) 1 7 (6 – 9) No No
France Yes (S, P)
416 - 
2,014
Yes (M, B) 19,484
50 (50 – 
50)
No No
Yes, limited 
(I, C)
Greece Yes (P) 4 7 (6 – 8)
Yes (M, B, 
BN)
17
26 (23 – 
30)
No No No
Italy Yes (S)
Yes (M, B, 
BN)
53 (52 – 
55)
No No
Yes, extensive 
(I, C)
Malta Yes 7
141 (134 – 
146)
Yes (M, B) ≥2 No No Yes, full (C)d
Portugal Yes (P) 27
149 (112 – 
224)
Yes (M, B) No Yes, limited Yes, full (I, C)
Spain Yes (P)
1,271 – 
1,458
Yes (M, 
B, H)
497 – 
2,229
Yes (7)
Yes, 
extensive
Yes, full (I, C)
a.     Full: substitution/maintenance treatment exists in nearly all prisons 
Extensive: exists in a majority of prisons but not in nearly all of them 
Limited: exists in more than a few prisons but not in a majority of them 
Rare: exists in just a few prisons
b.     Data is from 2008 or most recent year
c.     M = methadone, B = High-dosage buprenorphine, H = Heroin assisted treatment, 
BN = Buprenorphine-naloxone combination, SM = Slow-release morphine
d.     Available but no clients reported
1. European Monitoring Centre on Drugs and Drug Addiction (2010) Drug 
consumption facilities in Europe and beyond, in Harm Reduction Monograph: 
Harm reduction: evidence, impacts and challenges.
2. European Monitoring Centre on Drugs and Drug Addiction (2009) NR 2009.
3. European Monitoring Centre on Drugs and Drug Addiction (2010) Statistical 
Bulletin: Table HSR4. Year of introduction of needle and syringe programmes 
(NSPs) and types of programmes available in 2008. 
4. European Monitoring Centre on Drugs and Drug Addiction (2009) Statistical 
Bulletin: Table HSR-7. Availability and level of provision of selected health 
responses to prisoners in 26 EU countries, Norway and Turkey (expert ratings).
5. European Monitoring Centre on Drugs and Drug Addiction (2009) Statistical 
Bulletin: Figure HSR-2. Provision of substitution/maintenance treatment (OST) in 
the community and availability of OST programmes in the prison.
6. European Monitoring Centre on Drugs and Drug Addiction (2010) Statistical 
Bulletin: Table HSR9. Opioid substitution treatment in prison in EU 27, Croatia, 
Turkey and Norway.
7. European Monitoring Centre on Drugs and Drug Addiction (2010) Statistical 
Bulletin: Table HSR4. Year of introduction of needle and syringe programmes 
(NSPs) and types of programmes available in 2008.
8. Mathers B et al (2010) HIV prevention, treatment and care for people who inject 
drugs: A systematic review of global, regional and country level coverage. Lancet 
375 (9719):1014-28.
9. European Monitoring Centre on Drugs and Drug Addiction (2010) Statistical 
Bulletin: Figure HSR-3. Syringes distributed through specialised programmes per 
estimated IDU in 2008 or most recent year.
10. European Monitoring Centre on Drugs and Drug Addiction (2010) Statistical 
Bulletin: Table HSR1. Table HSR-1. Year of introduction of methadone maintenance 
treatment (MMT), high-dosage buprenorphine treatment (HDBT), buprenorphine/
naloxone combination, heroin-assisted treatment and slow-release morphine. 
11. Mathers B et al (2010) HIV prevention, treatment and care for people who inject 
drugs: A systematic review of global, regional and country level coverage. Lancet 
375 (9719):1014-28.
12. European Monitoring Centre on Drugs and Drug Addiction (2010) Statistical 
Bulletin: Figure HSR-1. Opioid substitution treatment clients as a percentage of the 
estimated number of problem opioid users, 2008 or most recent year available.
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Harm reduction in south europe
the authors would like to acknowledge the contributions of the 
following organisations in providing information for their respective 
countries:a
agência piaget para o Desenvolvimento (portugal); association 
Francaise pour la reduction des risques (France); auto support des 
usagers de Drogues (France); Itaca association (Italy); associación 
Benestar i Desenvolupament (spain); asociación de pacientes 
Dependientes a opiáceos (spain); Creu roja/red Cross (spain).
Harm reduction approaches are well-established in practice and policy in most countries in the south of Europe.  Coverage of NSPs and OST 
varies widely, with countries in the region boasting 
some of the highest (France, Spain and Portugal) and the 
lowest (Cyprus) coverage rates in Europe. Spain is the only 
country in the region that implements heroin-assisted 
treatment (HAT) and drug consumption rooms (DCRs).  
Harm reduction interventions are yet to be widely 
implemented, scaled up and adequately financed across 
the region. Limited integration among low threshold drug 
services and HIV, viral hepatitis and tuberculosis testing 
and treatment is a concern in all countries. Availability 
and coordination of harm reduction services in prisons 
and other closed settings remains very limited. There is 
an urgent need for provision and scale up of OST pre- 
and post-release from prison. Peer access to naloxone for 
overdose prevention and management is limited to Spain 
and Italy. Safer nightlife initiatives are implemented to 
varying degrees across the region and within countries. 
Harm reduction is explicitly supported in policy 
documents in all countries in the region. However, recent 
funding cuts to health and social welfare interventions and 
continued opposition by local and national authorities, 
have restricted the implementation of interventions such 
as DCRs and the scale up of existing interventions to 
levels sufficient to impact drug-related epidemics. 
As in other regions of Europe, involvement of 
people who use drugs at all levels of service design, 
implementation, monitoring and evaluation often 
takes the form of tokenistic consultations and requires 
sustained advocacy from civil society organisations and 
drug user groups. 
a   Questionnaire responses from Cyprus, Greece and Malta were not 
available at the time of writing. 
AdvocAcy PRioRitiES idEntifiEd by civil 
SociEty oRgAnizAtionS (cSoS) foR thiS 
REgion includE:a
  Implement evidence-based harm reduction 
services, particularly NSPs, and scale up provision 
of OST in prisons and other places of detention
  Implement or scale up DCRs
  Increase integration of harm reduction 
interventions, including overdose prevention 
programs, safer nightlife initiatives, and testing 
and treatment services for HIV, viral hepatitis and 
tuberculosis
  Improve the meaningful involvement of people 
who use drugs in service design, implementation, 
monitoring and evaluation.
nEEdlE And SyRingE ExchAngE 
PRogRAmmES (nSPs)
NSPs operate in the majority of states in South 
Europe with the exception of Cyprus, where the 
only existing NSP site has yet to receive government 
endorsement (see table 3.3.1).1 The latest available data 
indicate that the number of operational NSP sites varies 
widely from less than ten in Greece (4) and Malta (7), to 
up to 1,458 in Spain and 2,014 in France – the country 
with the largest reported number of sites in Europe.1 
Pharmacy-based NSPs are available in most countries 
in the region, except Italy, Malta and Cyprus, which rely 
on fixed and mobile outlets. NSPs operating through 
vending machines are available in some parts of Italy, 
Spain and France.1 
The rate of syringe distribution varies considerably 
across the region from low coverage in Greece with an 
estimated 7 (range 6-8) syringes distributed annually 
per person injecting drugs, to moderate coverage in 
Portugal with an estimated 149 (range 112-224) syringes 
per person injecting drugs per year.1 Barriers to scaling up 
NSPs include insufficient and insecure funding for harm 
reduction programmesc, public opposition to opening 
b France, Italy, Portugal and Spain.
c  Italy.
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new NSP sites in residential neighbourhoodsd and lack of 
political will or active political opposition.e 2 
Access to NSPs is reported to be limited or 
nonexistent outside of major cities and in rural areas, 
as well as outside of the city centre within cities where 
programmes are available.2 In Portugal and Spain, where 
service coverage is moderately high, restricted opening 
hours (i.e. regular operating hours, typically 9:00-17.00) 
pose barriers to access for many people who use drugs 
that circulate during late evenings, nights and weekends.2 
Additional barriers to accessing NSPs across the region 
include stigma toward people who use drugs,f fear of 
police surveillanceg and limited financial and human 
resources for distributing sterile injecting equipment 
through mobile and outreach NSPs.h 2
Problem cocaine use, and specifically use of crack 
cocaine, has been reported in France, Spain, Portugal 
and Italy.3 However, systematic data on the prevalence 
and patterns of crack use and targeted harm reduction 
responses for this user group remains limited and tends to 
be under-represented in more widely available estimates 
of regular cocaine users.3  
Targeted harm reduction responses for crack cocaine 
use are not implemented systematically anywhere in the 
region. The few existing interventions in Portugal, France 
and Spain are initiated by NGOs without any government 
support. In Spain and Portugal, where users are reported 
to smoke crack using handmade pipes fashioned out of 
syringe or methadone containers, some NSPs distribute 
aluminum foil.2 In Portugal several outreach teams also 
distribute crack smoking kits as part of an experimental 
study evaluating the acceptance of this intervention 
among people who use drugs.18 Elsewhere in the region, 
crack smoking kits are reportedly available only through 
a small number of drug services in Paris.2 In the absence 
of ammonia – reportedly the preferred substance used to 
cook crack cocaine – some NGOs in Catalonia distribute 
sodium bicarbonate.3 
d  Spain.
e  Portugal, Italy.
f  Spain.
g Spain.
h Portugal.
oPioid SubStitution thERAPy (oSt)
Methadone maintenance treatment (MMT) and 
buprenorphine maintenance treatment (BMT) are 
available in all countries in South Europe, with Greece 
and Italy also providing buprenorphine-naloxone 
combination therapy (see table 3.3.1). HAT is available in 
Granada in the South of Spain in the context of the PEPSA 
trial.4 5 6 
The most recent data indicate that provision varies 
across the region, from less than five OST sites in Cyprus 
(1) and Malta (≥2) to between 497 and 2, 229 sites in 
Spain and 19,484 in France.7 A more accurate indicator 
of service coverage is the percentage of people using 
opioids enrolled in OST programmes;10 however, available 
data is incomplete.8 Of the countries for which data is 
available, only France and Italy provide high coverage of 
OST as defined by WHO, UNODC and UNAIDS (i.e. at least 
40% of the total number of people using opioids enrolled 
in OST).9 
Service access and uptake is limited by several 
factors, including insufficient geographical coverage 
within countries,i strict initiation criteriaj and lengthy 
waiting lists.k 2 In some countries, the poor availability of 
flexible dosing (i.e. individualized and ‘take-home’ doses) 
of MMT and BMT and the necessity to visit the dispensing 
centre daily act as barriers to access for some individuals.l 
2 In Portugal for instance, where MMT is the leading form 
of OST dispensed, its administration in insufficient dosesm 
10 may act as a barrier to treatment effectiveness.2 
In most countries where data is available, accredited 
general practitioners (GPs) can legally initiate OST, 
but the degree to which they do so varies.10 2 OST, and 
particularly MMT, remain stigmatised among people who 
inject drugs,n as well as among GPs.o 2  For instance, in 
France, approximately two-thirds of GPs who are licensed 
to prescribe MMT and BMT do not do so, thus limiting 
accessibility for individuals that reside far from major 
dispensing centers and in rural areas.2 In Portugal, strict 
OST licensing requirements for practitioners act as an 
additional barrier to its wider accessibility.2 
Limited integration and effective coordination 
i    France, Italy, Spain.
j    France, Spain, Portugal. 
k   Portugal, Spain.
l    France, Spain, Portugal.
m According to the WHO, UNODC and UNAIDS, an adequate dose of 
methadone consists of 60mg or more per day.
n  In France, for instance, there are reports of some people who use 
drugs purchasing methadone on the illicit black market in an attempt 
to avoid stigma by active peers. Similarly, some GPs working outside 
major cities avoid taking on patients who use drugs and initiating 
them on MMT or BMT due to the stigma it carries among their 
professional peers.
o  France, Spain, Portugal.
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between OST and broader health care services,p and a 
lack of national guidelines for OST provisionq pose further 
challenges to OST accessibility and scale up.2 
 
Drug consumption rooms (Dcrs)
Spain is the only country in South Europe that 
implements DCRs (see table 3.3.1).11 DCRs are often 
targeted at specific user groups depending on the route 
of drug administration.12 Of the seven DCRs in existence in 
Spain, two DCRs in Bilbao and Barcelona are targeted at 
people who smoke or inhale drugs, while the remaining 
five are directed at those who inject.2 CSOs reported a 
need to scale up consumption rooms for people who 
smoke or inhale drugs, as well as implement DCRs 
targeted at users who snort and sniff drugs.2 
Access to existing DCRs in Spain is limited by 
a number of factors, including narrow geographical 
coverage among provinces and outside of major cities, 
restricted opening hours, age restrictions for those under 
18 and regulations on the types of substances that can be 
consumed on the premises.2 Fear of arrest and perceived 
stigma pose additional barriers for some individuals. CSOs 
in all countries reported an urgent need for advocacy to 
increase the acceptability of this intervention and reduce 
the stigma associated with its use in the community and 
among people who use drugs.2 
In Portugal, no legal restrictions to DCRs exist, but 
approval must be secured by each city council. To date, 
there are no cities in Portugal that have approved the 
piloting or implementation of a DCR.2 On 19 May, 2009 
the drug user organization ASUD stirred public and high-
level political debate about DCRs in France by opening 
a “real/false” drug consumption room in Paris.13 The 
French Ministry of Health has subsequently approved 
the implementation of DCRs, but the Prime Minister 
continues to oppose this measure.14 As in other countries 
in the region where this intervention is not employed, the 
most significant barriers to implementation are lack of 
political will,r policy and legal restrictionss and negative 
public opinion.t2
p  France, Spain, Portugal.
q  Spain, Portugal. For instance, in Portugal MMT can only be prescribed 
by GPs working with the national Drug and Drug Dependence Institute 
(IDT), and MMT provision is not officially authorized by the IDT due to a 
lack of regulatory guidelines. MMT is provided only through some low-
threshold programmes implemented by NGOs and who cooperate 
with a licensed IDT doctor.
r  Italy, France, Portugal.
s  Italy, France.
t  Italy, Portugal. 
SEx woRk And hARm 
REduction
thierry Shaffaseur and Pye Jakobsson
Despite being implemented in many countries, 
harm reduction for sex workers is still a novel idea. Sex 
workers may experience a number of harms, including 
harms associated with drug use, vulnerability to HIV 
and other STIs, violence and discrimination. Harm 
reduction approaches can play an important role 
in protecting the human rights of sex workers, 
advocating for the decriminalisation of sex work 
and implementing strategies for the prevention of 
negative health outcomes. Such strategies can include 
peer outreach, provision of condoms and materials for 
safer drug use, labour regulations for the health and 
safety of sex workers, training in condom-negotiating 
skills and tips and self-support networks for street-
based sex workers.
In many countries services targeting sex workers 
tend to have a “rescue” focus. The assumption is that 
sex work is not a profession one can freely choose 
and it is therefore always harmful to the individual. 
Providing access to health care, such as HIV prevention 
interventions, is often viewed as secondary to 
encouraging people to leave sex work. Approaching 
sex work from a harm reduction perspective not 
only respects the choice of the individual, but it also 
ensures that basic human rights, such as the right 
to the highest obtainable standard of health, are 
considered as part of interventions. This is particularly 
true for sex workers who use drugs, who experience 
the double stigma of engaging in multiple illicit and 
generally, illegal, practices. 
It is crucial that alliances between harm 
reduction practitioners and sex work organizations 
are strengthened, and harm reduction approaches for 
sex work are systematically researched, implemented 
and evaluated.  
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hiv, viRAl hEPAtitiS And 
tubERculoSiS (tb) SERvicES
HIV testing and treatment services
Implementation and scale up of harm reduction 
programmes has led to sustained low HIV incidence 
among people who inject drugs across this region. 
However, some countries reported continuing 
barriers to HIV testing and treatment access despite its 
availability free of charge. In Spain, these include the 
lack of anonymity assurance around the disclosure of 
test results, stigma associated with a positive HIV test 
result, and lack of awareness among users around the 
availability of testing services.2  In the Spanish context, 
a significant gap is the lack of culturally-specific harm 
reduction services for migrants who use drugs.3 In 
northern Portugal, mobile VCT is employed widely to 
reach people who inject drugs that do not attend health 
centres.2 
Where data is available, the number of people 
who inject drugs living with HIV that are receiving 
antiretroviral therapy (ART) in the region varies from 
110 in Greece (ratio unknown) to 39 524 (ratio >63/100 
people who inject drugs living with HIV) in Spain.14 The 
social exclusion and poverty that many people who inject 
drugs living with HIV experience is reported to impede 
access and adherence to antiretroviral treatment (ARV).2 
Additional barriers in Portugal are posed by doctors’ 
refusal to initiate people actively using drugs on ART 
and a lengthy, demanding process from diagnosis to 
treatment.2 
Viral hepatitis testing and treatment 
services
Hepatitis B vaccination programmes targeted at 
high-risk groups, including people who use drugs, are 
implemented in France, Italy, Spain and Greece.15 Greece, 
Spain, Italy and Portugal also implement HBV vaccination 
programs in prisons.17 In Portugal, the requirement to pay 
for HBV vaccination is reported to deter some people 
who use drugs from accessing this service.2 An outreach 
team in the North of Portugal has circumvented this 
obstacle by negotiating free access to HBV vaccination for 
its clients with the regional health administration.16 
Several barriers continue to restrict access to HCV 
testing and treatment. In a number of countries in the 
region,u lack of awareness of transmission routes for HCV 
and limited peer support networks prevent some users 
from seeking an HCV test.2 In Portugal and Spain, CSOs 
u  France, Spain, Portugal.
report that the lack of a rapid test for HCV deters some 
people who inject drugs that have vein problems from 
seeking a test.2 Moreover, after undergoing a test, many 
users in Spain reportedly lack the resources to return for 
subsequent diagnosis and treatment.2 
Barriers to accessing HCV treatment are numerous, 
even in countries where the state subsidizes most or all 
costs  associated with treatment.v  Negative associations 
with HCV treatment and its side effects deter some users 
from seeking treatment.17 In Spain, access criteria, such 
as being drug-free, prevent some people who use drugs 
from benefitting from available treatments.w Although no 
formal criteria or guidance for prescribing HCV treatment 
exists in Portugal, many GPs refuse to initiate active 
opiate, cocaine and cannabis users on treatment due 
to false assumptions, including that adherence among 
people who use drugs tends to be low.2 18 19 Moreover, 
referral processes may be lengthy and arduous, requiring 
registration with the relevant city council and several 
health service visits.2 
Tuberculosis testing and treatment services
Several factors impede TB detection and 
management among people who use drugs in this region. 
In Spain and Portugal, CSOs report that many users access 
testing and treatment services only in the late stages of 
TB.2 In Portugal, distrust of the public health care system 
and fear of discrimination from health professionals pose 
additional barriers to testing and take up. Screening 
processes that involve multiple appointments are a 
significant deterrent to take up of testing by people who 
use drugs, as do requirements to visit dispensing centres 
daily for treatment administration.20  In Spain, public 
health agencies have the authority to coerce a patient 
who refuses to undergo treatment for TB to do so through 
a court order.21
hARm REduction in PRiSonS
Spain is the only country in the region that 
implements NSPs extensively in prisons.22 23 
OST is available for initiation and continuation in 
prisons in Portugal, Spain, Italy and France, but service 
coverage varies between countries and among prisons.25 
In Malta, OST is continued in prison if the inmate was 
already enrolled in the programme prior to arrest; 
however, there are no inmates presently accessing this 
service.27 According to data from 2009, 12% of all prisoners 
v  For instance, France.
w  Access criteria includes being drug-free.
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in Spain received MMT.26 In France, this intervention 
remains limited, but anecdotal reports confirm that 
provision has increased since 2004.27 There is no OST 
available in prisons in Greece, and in Portugal prisoners 
may be denied access if they are actively using drugs.2 
Across the region, poor coordination of OST continuity 
upon release from prison poses additional barriers to 
managing drug-related harms.2 
Several factors act as barriers to accessing prison-
based NSPs where these exist, and implementing them 
where they do not exist. CSOs noted that it is often 
individual prison directors who ultimately decide 
whether or not to implement a particular programme.2 
In some Spanish prisons, prison staff are reported to 
coerce prisoners into providing information on peers 
who utilise the service.2 The only pilot NSP in Portuguese 
prisons was terminated in 2007 within a few months due 
to logistical challenges, methodological inconsistencies 
and resistance from prison guards and other prison 
professionals.22
Ideological arguments by policy-makers in France, 
Spain, Italy and Portugal that deny the existence of 
drug use in prisons, focusing instead on drug control 
and abstinence-based measures, continue to challenge 
implementation and scale up of evidence-based harm 
reduction interventions in prisons.2 
ovERdoSE RESPonSES
Overdose prevention responses including provision 
of overdose training material to people who use drugs, 
individual overdose risk assessment, overdose response 
training and risk education on drug-related deaths are 
limited, rare or nonexistent in most countries across the 
region.28 The exceptions are Greece and Italy, where 
responses are extensive, x and Portugal, where it is 
reported that overdose information materials and risk 
education training are widely implemented.y 30
Availability of naloxone and its distribution by 
peers varies among countries in the region. In some 
parts in Spain, in particular Catalonia, CSOs distribute 
naloxone among peers upon request and provide 
trainings on naloxone administration and management.2 
In Italy, naloxone is available for purchase at pharmacies 
without a medical prescription, and outreach workers 
may administer it directly to the individual in case of 
an overdose.2 In France, despite naloxone’s legal status 
x  ‘Extensive’ is defined by the EMCDDA (2010) “a majority of the target 
group (but not nearly all of them) have received the service during the 
last year at least once.”
y  i.e. to nearly all members of target group have received the service 
during the last year at least once, and in nearly all cities or towns 
where the size of the drug user population is sufficient for the 
implementation of the intervention.
and its availability for sale at pharmacies, take up by 
people who use drugs, their families and communities is 
reported to be low.19 In Portugal naloxone is not available 
to outreach workers and peers,z but as reported here and 
across the region, it is a ‘highly sought’ intervention in 
‘short supply.’2 
Additional factors that limit effective prevention 
and management of overdose in the region include legal 
barriers around its administration and transportability, 
and lack of awareness among people who use drugs, 
their families and communities about the benefits of 
naloxone as an evidence-based method for managing 
drug overdose.2 
hARm REduction foR REcREAtionAl 
dRug uSE 
Safer nightlife initiatives, including outreach, 
counseling in recreational settings, information and 
education campaigns and materials, are implemented in 
all countries in the region to varying degrees. 
Harm reduction initiatives are implemented in Italy 
and Portugal, but coverage varies widely from region to 
region.2 The most extensive harm reduction programs in 
recreational settings exist in Spain, where multi-regional 
projects such as Energy Control have been operating 
since 1997 with explicit policy support.aa 29 Safer nightlife 
initiatives across the country provide risk reduction 
trainings to recreational professionals such as security, 
bartenders and event promoters, utilise peer outreach 
on- and off-site, employ a variety of new media outlets, 
including online tools such social networking sites, 
Bluetooth and text message to disseminate information 
to party-goers.29 Energy Control and Ailaket, a project in 
the Basque region, also provide an instant alert system to 
users, health care referral systems and monitoring centres 
for a wide range of substances used in recreational 
settings. 
Spain is the only country in the region where 
on-site pill testing in recreational settings is widely 
implemented.29 In Portugal, only one outreach team, 
Check-in, is authorized to test drugs on-site in recreational 
settings.30 In France, pill testing was legally permitted as a 
harm reduction measure in raves and other party settings 
until 2004.19
Several challenges remain to the implementation 
and scale up of safer nightlife initiatives in most countries 
z  Outside of emergency services in Portugal, naloxone is also 
administered by nurses as part of one outreach team.
aa Harm reduction in recreational settings is explicitly mentioned in 
Spain’s National Drug Strategy and in the Libre Blanc De Prevenció, 
Spain’s official ‘white book of prevention’ that details nationally-
recognised good practices. 
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in the region. With the exception of Spain, where 
initiatives are subsidized by the state, existing projects 
elsewhere tend to be small-scale, volunteer-run or 
minimally funded.2 The limited reach of interventions to 
settings outside the ‘traditional’ rave and techno scenes 
suggests that diversified approaches to delivering safer 
nightlife initiatives may be required.29 CSOs expressed 
a need to move beyond information and education 
campaigns to disseminating an extensive range of 
materials in recreational settings, including earplugs, 
sniff tubes, personal drug use assessments, alcohol 
breathalyzers and condoms. 
 
Policy SuPPoRt foR hARm 
REduction
All countries in the region, with the exception of 
Italy, make explicit reference to harm reduction in their 
national drug policy documents. In practice, support for 
harm reduction varies widely among regions in Italy, and 
most harm reduction programmes are still in pilot stage.31 
Along with Sweden, Italy has played a consistent role in 
opposing the European position on harm reduction 
during negotiations at the UNODC General Assembly.
Across the region, implementation of harm reduction 
programmes generally rests with local governments.2 
In some countries where formal support for 
NSPs and OST exists (i.e. France and Portugal), public 
acknowledgement of support for broader harm reduction 
interventions such as DCRs and pill testing is scarce.2
Where  available, financial support for harm 
reduction varies within countries. For instance, 
while Barcelona and the Catalonia region benefit 
from partial government grants, this support is not 
available consistently to all regions.2  Although the 
Portuguese government co-finances all NSP services 
across the country, this support is insufficient and 
increasingly delayed due to the economic crisis.34 Other 
conditionalities on support include a two-year cap on 
project funding, which challenges the sustainability and 
continuity of several programmes around the country.19 
France’s CAARUD framework guarantees sustainable 
funding to CSOs for 10 years provided that they meet 
strict monitoring and evaluation criteria, but some 
community-based organisations are either unable or 
unwilling to join.29 Across South Europe, recent funding 
cuts to health and social welfare interventions, and 
opposition by some local authorities have restricted the 
scale up of interventions to levels sufficient to impact on 
drug-related epidemics.2 
dRug uSER involvEmEnt in hARm 
REduction RESPonSES
Meaningful involvement of people who use drugs 
in service design, implementation, monitoring and 
evaluation is very limited across South Europe. CSOs 
report that user representation in the form of councils 
with consultative status to various drug and health 
services is present in some areas in France, Italy and 
Spain.3 However, while users are physically represented 
at the individual and organizational levels, their level of 
involvement is often tokenistic.2 OST and drug treatment 
centers in Spain operate under regulations specifying the 
involvement of two user advisors in clinical team meetings, 
Safer nightlife and the nEw 
imPlEmEntAtion project
thierry charlois and claudia Stoicescu
The high prevalence of synthetic drug and 
polydrug use in recreational settings such as clubs, 
raves or festivals makes these important venues 
for implementing harm reduction interventions. 
However, setting-based interventions remain scarce 
in most countries in Europe.
An innovative multi-country projecta, 
the ‘Nightlife, Empowerment and Well-being 
Implementation’ project (NEW Implementation), aims 
to respond to emerging challenges in recreational 
settings including party tourism, new drug use trends, 
the need to improve peer empowerment within the 
nightlife community, as well as filling geographic 
coverage gaps. The three-year project started in early 
2011, and aims to develop, implement and exchange 
harm reduction guidelines, standards and good 
practices for recreational settings. 
As part of the initiative, partners plan to 
implement a range of comprehensive activities to 
address drug use in recreational settings across 
Europe. This includes field interventions at six major 
international festivals in Europe and introduction 
of safer party labels in 12 EU cities involving the 
local communities (“Party +” network), as well 
as development of an early warning system on 
dangerous substances and new trends. 
a Austria, Belgium, France, Germany, Italy, Netherlands, Portugal, 
Spain, with collaborating partners also located in Lithuania, 
Romania, Slovenia and the United Kingdom.
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but in practice these rules are rarely implemented.32
Levels of representation of autonomous groups of 
people who use drugs working toward self-determination 
agendas in the region vary between countries. In France, 
representation of people who use drugs has reportedly 
weakened over the past decade. For instance, the number 
of ASUD member groups in France has been steadily 
decreasing, from 26 in 1998 to only four in 2010.29 In 
Portugal, however, people who use drugs have become 
increasingly active, with CASO, a new national user group 
founded in 2010, now reporting more than 30 members.16
Meaningful user involvement in the region is 
hampered by the perception that people actively using 
drugs do not have the necessary technical expertise 
to contribute to agendas and services affecting their 
interests.2 There is an urgent need for CSOs and user 
groups to advocate for the empowerment of people 
who use drugs through meaningful involvement in 
policy-making and service provision, including design, 
implementation, monitoring and evaluation.
civil SociEty And AdvocAcy
Civil society organisations advocating for harm 
reduction operate at the local, national, regional and 
international levels in the South Europe region.3
In France, Spain and Portugal, advocacy activities 
are partly funded by local or national governments and 
generally led and implemented by CSOs.3 Additional 
funding sources reported by CSOs in the region include 
the European Commission and European regional 
networks.34 There is no state support or funding provided 
for civil society organisations advocating for harm 
reduction in Italy.35 
National harm reduction networks operate formally 
in France and Portugal, but coordination of local and 
national advocacy priorities among CSOs is also reported 
in Spain.2 At the time of publication, CSOs advocating for 
harm reduction in Italy were in the process of mobilizing 
around a national network with a shared platform 
and agenda.35 The majority of CSOs in this region are 
also involved regionally at the European level and 
internationally through participation in several networks 
such as EuroHRN, CLAT, ENCOD, Correlation, and DCD, or 
through membership in international organisations such 
as Harm Reduction International. 
In all countries where information was available, 
CSOs identified the following advocacy priorities:
  Implement evidence-based harm reduction 
services, particularly NSPs, and scale up provision 
of OST in prisons and other places of detentionab
  Implement or scale up DCRsac
  Increase integration of harm reduction 
interventions, including overdose prevention 
programs, safer nightlife initiatives, and testing 
and treatment services for HIV, viral hepatitis and 
tuberculosisad
  Improve the meaningful involvement of people 
who use drugs in service design, delivery, 
monitoring and evaluationae
Other advocacy priorities in the region included 
the development of national standards for distributing 
drug snorting and smoking materials through NSPs,af 
regulation of drug testing programs in recreational 
settings,ag and standardization of national access criteria 
to low-threshold harm reduction services.ah
ab  France, Spain, Italy and Portugal. 
ac  France, Spain, Portugal.
ad  France, Italy, Portugal and Spain. 
ae  France, Portugal, Spain.
af   Portugal.
ag  Portugal.
ah  Spain.
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